Document:

EX-10.14

 Exhibit 10.14 

Certain identified information has been excluded from this exhibit because it is both not material and 

is the type that the registrant treats as private or confidential. Information that was omitted has been 

noted in this document with a placeholder identified by the mark “[***]”. 

Master Manufacturing Services Agreement 

Effective Date: November 12, 2019 

PARTIES 
 PATHEON
INC. 
 a company existing under the laws of Canada, with a place of business at 111 Consumers Drive, Whitby, Ontario L1N 5Z5
(“Patheon”), 
 - and - 

AMYLYX PHARMACEUTICALS, INC. 

a corporation existing under the laws of the State of Delaware, with its principal place of business located at 43 Thorndike Street, Cambridge,
MA 02141 (“Client”). 

 TABLE OF CONTENTS 

 

							
	 	 	 	  	Page	 
	 1.  Structure of Agreement and Interpretation
	  	 	1	 
	 1.1
	 	Master Agreement	  	 	1	 
	 1.2
	 	Product Agreements	  	 	1	 
	 1.3
	 	Definitions	  	 	1	 
	 1.4
	 	Interpretation	  	 	5	 
	 2.  Patheon’s Manufacturing Services
	  	 	6	 
	 2.1
	 	Manufacturing Services	  	 	6	 
	 2.2
	 	Subcontracting	  	 	6	 
	 3.  Client’s Obligations
	  	 	6	 
	 3.1
	 	Payment	  	 	6	 
	 3.2
	 	Processing Instructions	  	 	6	 
	 3.3
	 	API and Components	  	 	7	 
	 3.4
	 	Packaging and Artwork	  	 	8	 
	 4.  Price and Price Adjustments
	  	 	8	 
	 4.1
	 	First Year Pricing	  	 	8	 
	 4.2
	 	Annual Price Adjustments	  	 	8	 
	 4.3
	 	Price Adjustments at any Time	  	 	9	 
	 5.  Purchasing Product
	  	 	9	 
	 5.1
	 	Orders and Forecasts	  	 	9	 
	 5.2
	 	Obsolete Stock	  	 	11	 
	 5.3
	 	Storage	  	 	11	 
	 5.4
	 	Invoices and Payment	  	 	12	 
	 5.5
	 	Delivery and Shipping	  	 	12	 
	 6.  Product Claims and Recalls
	  	 	12	 
	 6.1
	 	Product Claims	  	 	12	 
	 6.2
	 	Product Recalls and Returns	  	 	13	 
	 6.3
	 	Disposition of Deficient Product	  	 	14	 
	 7.  Co-operation and Regulatory
Affairs
	  	 	14	 
	 7.1
	 	Governance	  	 	14	 
	 7.2
	 	Governmental Agencies	  	 	14	 
	 7.3
	 	Records	  	 	15	 
	 7.4
	 	Audits	  	 	15	 

  
 -i- 

 TABLE OF CONTENTS 

(continued) 
  

							
	 	 	 	  	Page	 
	 7.5
	 	Regulatory Filings	  	 	15	 
	 7.6
	 	Release	  	 	16	 
	 7.7
	 	Withdrawal on Completion	  	 	16	 
	 8.  Term and Termination
	  	 	16	 
	 8.1
	 	Initial Term	  	 	16	 
	 8.2
	 	Termination for Cause	  	 	16	 
	 8.3
	 	Obligations on Termination	  	 	18	 
	 8.4
	 	Technology Transfer	  	 	19	 
	 9.  Representations, Warranties and Covenants
	  	 	19	 
	 9.1
	 	Authority	  	 	19	 
	 9.2
	 	Client Warranties	  	 	19	 
	 9.3
	 	Patheon Warranties	  	 	20	 
	 9.4
	 	Permits	  	 	20	 
	 9.5
	 	No Warranty	  	 	21	 
	 10.  Liability and Remedies
	  	 	21	 
	 10.1
	 	Consequential and Other Damages	  	 	21	 
	 10.2
	 	Limitation of Liability	  	 	21	 
	 10.3
	 	Patheon Indemnity	  	 	22	 
	 10.4
	 	Client Indemnity	  	 	22	 
	 10.5
	 	Reasonable Allocation of Risk.	  	 	23	 
	 10.6
	 	Validation Batches	  	 	23	 
	 11.  Confidentiality
	  	 	23	 
	 11.1
	 	Confidential Information	  	 	23	 
	 11.2
	 	Use of Confidential Information	  	 	23	 
	 11.3
	 	Exclusions	  	 	24	 
	 11.4
	 	Photographs and Recordings	  	 	24	 
	 11.5
	 	Permitted Disclosure	  	 	24	 
	 11.6
	 	Marking	  	 	25	 
	 11.7
	 	Return of Confidential Information	  	 	25	 
	 11.8
	 	Remedies	  	 	25	 
	 12.  Intellectual Property
	  	 	25	 
	 12.1
	 	Inventions	  	 	25	 

  
 -ii- 

 TABLE OF CONTENTS 

(continued) 
  

							
	 	 	 	  	Page	 
	 12.2
	 	Intellectual Property	  	 	26	 
	 13.  Miscellaneous
	  	 	26	 
	 13.1
	 	Insurance	  	 	26	 
	 13.2
	 	Independent Contractors	  	 	26	 
	 13.3
	 	No Waiver	  	 	27	 
	 13.4
	 	Assignment	  	 	27	 
	 13.5
	 	Force Majeure	  	 	27	 
	 13.6
	 	Additional Product and Services	  	 	28	 
	 13.7
	 	Notices	  	 	28	 
	 13.8
	 	Severability	  	 	29	 
	 13.9
	 	Entire Agreement and Amendment	  	 	29	 
	 13.10
	 	Other Terms	  	 	29	 
	 13.11
	 	No Third Party Benefit or Right	  	 	29	 
	 13.12
	 	Execution in Counterparts	  	 	29	 
	 13.13
	 	Use of Name	  	 	29	 
	 13.14
	 	Taxes	  	 	30	 
	 13.15
	 	Governing Law and Jurisdiction	  	 	31	 
	 13.16
	 	Dispute Resolution	  	 	31	 
	 APPENDIX 1 - Form of Product Agreement
	  	 	1	 
	 APPENDIX 2 - Dispute Resolution
	  	 	1	 
	 Negotiation
	  	 	1	 
	 Mediation
	  	 	1	 
	 Technical Disputes
	  	 	1	 
	 APPENDIX 3 - API Yield Calculation
	  	 	1	 
	 Actual Annual Yield
	  	 	1	 
	 Target Yield and Credit Calculation
	  	 	1	 
	 Limits on API Liability
	  	 	2	 
	 APPENDIX 4 - Price Adjustments
	  	 	1	 
	 Price Adjustment Calculation Due To Inflation
	  	 	1	 
	 Price Adjustment Calculation Due To Currency Fluctuation
	  	 	1	 

  
 -iii- 

	1.	 Structure of Agreement and Interpretation 

 

	1.1	 Master Agreement. 

This Master Manufacturing Services Agreement (the “Agreement”) establishes the general terms and conditions under which Patheon or
any Affiliate of Patheon in the business of performing manufacturing services may perform Manufacturing Services for Client or any Affiliate of Client. This master form of agreement is intended to allow the parties, or any of their Affiliates, to
contract for the manufacture of Product through Patheon’s global network of manufacturing sites by entering into specific Product Agreements without having to re-negotiate the general terms and conditions
that apply. 
  

	1.2	 Product Agreements. 

This Agreement is structured so that Product Agreements may be entered into by the parties (or their Affiliates) for the manufacture of Product
at any Patheon manufacturing site. Each Product Agreement will be governed by and will incorporate the terms and conditions of this Agreement, except to the extent that the parties to the Product Agreement expressly modify the terms and conditions
of this Agreement in the Product Agreement. Unless otherwise agreed by the parties, each Product Agreement will be substantially in the general form, and contain the information referred to, in Appendix 1. In the event of any conflict between the
terms of this Agreement and a particular Product Agreement, the terms and conditions of the Product Agreement shall control if so specifically stated; otherwise, the terms and conditions of this Agreement shall control for all purposes. 

 

	1.3	 Definitions. 

The following terms will, unless the context otherwise requires, have the respective meanings set out below and grammatical variations of these
terms will have corresponding meanings: 
 “Affiliate” means: 

 

	 	(a)	 a business entity which owns, directly or indirectly, a controlling interest in a party; or

  

	 	(b)	 a business entity which is controlled by a party, either directly or indirectly; or 

 

	 	(c)	 a business entity, the controlling interest of which is directly or indirectly common to the majority ownership
of a party; 

 For this definition, “control” means the lawful right to determine (by ownership of shares or
otherwise) the election of the majority of directors (or equivalent managers) of a business entity; 
 “Annual Volume”
means, for the purpose of the Price, Patheon’s assumed volume of Product to be manufactured in any Year as set out in the “Annual Volume Forecast” section of Schedule A of the applicable Product Agreement. 

“API” means the active materials listed in the applicable Product Agreement (references to “Active Materials”
or “Active Pharmaceutical Ingredient” in documents forming part of this Agreement or of a Product Agreement will mean “API”); 

“API Credit Value” means the value of the API for certain purposes of this Agreement, as set out in the applicable
Product Agreement; 

  
 1 

 “Applicable Laws” means: (i) for Patheon, the Laws of the
jurisdiction where the Manufacturing Site is located; and (ii) for Client and the Product, the Laws of all jurisdictions where Product is manufactured, distributed, and marketed as these are agreed by the parties in the Product Agreement; 

“Authority” means any governmental or regulatory authority, department, body or agency or any court, tribunal, bureau,
commission or other similar body, whether federal, state, provincial, county or municipal, with competent jurisdiction over a party, the Manufacturing Services, or the relevant Product (or its use); 

“Batch” means a quantity of Product in kilograms or units as provided under the applicable Product Agreement. 

“Business Day” means a day other than a Saturday, Sunday or a day that is a statutory holiday in Ontario, Canada; 

“Capital Equipment Agreement” means the separate agreement that the parties may enter into that addresses the rights
and responsibilities of the parties regarding capital equipment and facility modifications that may be required to perform the Manufacturing Services under a particular Product Agreement; 

“cGMPs” means, as applicable, current good manufacturing practices as described in: 

 

	 	(a)	 Parts 210 and 211 of Title 21 of the United States’ Code of Federal Regulations; 

 

	 	(b)	 Commission Directive (EU) 2017/1572 (art. 2); and 

 

	 	(c)	 Division 2 of Part C of the Food and Drug Regulations (Canada); together with current final industry-accepted
Health Canada, FDA and EMA guidance documents pertaining to manufacturing and quality control practice, all as updated, amended and revised from time to time; 

“Client Intellectual Property” means: Intellectual Property provided to Patheon by or on behalf of Client, or generated
or derived by Client before the Effective Date of this Agreement or by Patheon while performing any Manufacturing Services which Intellectual Property is specific to, or dependent upon, the Product; 

“Client-Supplied Components” means those Components supplied or to be supplied by or on behalf of Client as identified
in Schedule A of a Product Agreement; 
 “Components” means, collectively, all packaging components, raw materials,
ingredients, and other materials (including labels, product inserts and other labelling for the Products) required to manufacture or package Product in accordance with the Processing Instructions, other than the API; 

“Confidential Information” has the meaning specified in Section 11.1; 

“Conversion Fee” means the capital price for performing the Manufacturing Services excluding the cost of Components as
specified in the Product Agreement; 
 “DEA” means the Drug Enforcement Administration of the United States
Department of Justice; 

  
 2 

 “Deficient Product” has the meaning specified in
Section 6.1(a); 
 “Disclosing Party” has the meaning specified in Section 11.1; 

“EMA” means the European Medicines Agency; 

“FDA” means the United States Food and Drug Administration; 

“Firm Order” has the meaning specified in Section 5.1(d); 

“Health Canada” means the department of the Canadian Government known as Health Canada and includes, among other
relevant branches, the Therapeutic Products Directorate and the Health Products and Food Branch Inspectorate; 
 “Initial Product
Term” has the meaning specified in Section 8.1; 
 “Intellectual Property” includes, without
limitation, rights in patents, patent applications, formulae, trademarks, trademark applications, trade-names, Inventions, copyrights, industrial designs, confidential information, trade secrets, materials, data, writings, and know how; 

“Invention” means information about any innovation, improvement, development, discovery, computer program, device,
trade secret, method, process, technique or the like, whether or not written or otherwise fixed in any form or medium, regardless of the media on which it is contained and whether or not patentable or copyrightable; 

“Inventory” means, at a point in time, all inventories of Components and work-in-process under Patheon’s care or control used for the manufacture or packaging of Product; 

“Launch Period” means the [***] period commencing on the date of the first commercial sale of a Product with all
Regulatory Approvals to the general public in the Territory and ending on the [***] anniversary of the first commercial sale. For example, if the first commercial sale occurred on August 1,2020 then the Launch Period would terminate on [***].

 “Laws” means all laws, statutes, ordinances, regulations, rules, by-laws,
judgments, decrees or orders of any Authority; 
 “Local Currency” has the meaning specified in Appendix 4; 

“Long Term Forecast” has the meaning specified in Section 5.1(a); 

“Manufacturing Services” means the manufacturing, quality control, quality assurance, stability testing, packaging, and
related services, as set out in this Agreement or in any Product Agreement, for the manufacture of Product for distribution in the Territory; 

“Manufacturing Site” means the facility identified in a Product Agreement where the Manufacturing Services will be
performed; 
 “Minimum Market Requirement” has the meaning specified in Section 2.1; 

  
 3 

 “Minimum Order Quantity” means, for each manufacturing campaign
ordered, the minimum number of units, batches or kilograms of a Product that Client must purchase, as set out in Schedule A of the applicable Product Agreement; 

“Obsolete Stock” has the meaning specified in Section 5.2(b); 

“Patheon Competitor” means a business that derives greater than fifty (50%) percent of its revenues from performing
contract pharmaceutical or biopharmaceutical development or commercial manufacturing services; 
 “Patheon Intellectual
Property” means Intellectual Property generated or derived by Patheon or its Affiliates before performing any Manufacturing Services, developed by Patheon while performing the Manufacturing Services, or otherwise generated or derived
by Patheon in its business which Intellectual Property is not specific to or dependent upon the Product or Client’s confidential information related to the Product including, without limitation, Inventions and Intellectual Property which apply
to manufacturing processes or the formulation or development of drug products or drug delivery systems unrelated to the specific requirements of the Product and specifically excluding all Client Intellectual Property and Client Confidential
Information; 
 “Partial Assignment” means the asset sale by Client of a Product. 

“Price” means the fees to be charged by Patheon for: 

 

	 	(a)	 performing the Manufacturing Services; 

 

	 	(b)	 the cost of Components (other than Client-Supplied Components); and 

 

	 	(c)	 any separate cost items and other fees, 

as set out in Schedule A of the applicable Product Agreement; 

“Processing Instructions” means the agreed file, for each Product, which contains documents relating to the Product,
including, without limitation: 
  

	 	(a)	 quality control testing methods for API and Components; 

 

	 	(b)	 manufacturing instructions, directions, and processes; 

 

	 	(c)	 any storage requirements for the API, Components, or Product; 

 

	 	(d)	 all environmental, health and safety information for the Product including material safety data sheets; and

  

	 	(e)	 the finished Product quality control testing methods, packaging instructions and shipping requirements for the
Product; 

 “Product” means a product listed in Schedule A of a Product Agreement; 

“Product Agreement” means the agreement between Patheon and Client (or their applicable Affiliates) substantially in
the form set out in Appendix 1 under which Patheon will perform Manufacturing Services; 

  
 4 

 “Product Claims” has the meaning specified in Section 6.1(a);

 “Quality Agreement” means a separate agreement that sets out the quality assurance standards for the Manufacturing
Services; 
 “Recall” has the meaning specified in Section 6.2(a); 

“Recipient” has the meaning specified in Section 11.1; 

“Regulatory Approval” has the meaning specified in Section 7.5(a); 

“Regulatory Authority” means the FDA, EMA, and Health Canada and any other foreign regulatory agencies competent to
grant marketing approvals for pharmaceutical or biopharmaceutical products, including the Products, in the Territory; 
 “Release
Date” means in relation to each batch of Product the scheduled date by which the Product will be released by Patheon’s quality department (by confirmation or certification) as agreed in the Quality Agreement and made available
for shipment, and as confirmed by Patheon in a Firm Order; 
 “Representatives” means, a party’s directors,
officers, employees, advisers, agents, consultants, subcontractors, service partners or professional advisors; 
 “Rolling
Forecast” has the meaning specified in Section 5.1(b); 
 “Technical Dispute” has the meaning
specified in Appendix 2; 
 “Territory” means the geographic area described in a Product Agreement where Product
manufactured by Patheon will be distributed by or on behalf of Client; 
 “Third Party Rights” means the Intellectual
Property of any third party; 
 “VAT” has the meaning specified in Section 13.14; and 

“Year” means in the first year of this Agreement or a Product Agreement, the time from the Effective Date up to and
including December 31 of the same calendar year, and after that will mean a calendar year. 
  

	1.4	 Interpretation. 

The division of this Agreement into Sections, Subsections, Appendices and Schedules, and the insertion of headings, are for convenience of
reference only and will not affect the interpretation of this Agreement. Unless otherwise indicated, any reference in this Agreement to a Section, Appendix or Schedule refers to the specified Section, Appendix or Schedule to this Agreement. In this
Agreement, the term “this Agreement” and similar expressions refer to this Agreement as a whole and not to any particular part, Section, Appendix or Schedule of this Agreement. Except as otherwise expressly stated or unless
the context otherwise requires, all references to the singular will include the plural and vice versa. 

  
 5 

	2.	 Patheon’s Manufacturing Services 

 

	2.1	 Manufacturing Services. 

In accordance with the terms of this Agreement, Patheon will timely perform the Manufacturing Services as set out in the relevant Product
Agreement for the Price and in accordance with the Quality Agreement. Subject to the preceding sentence, Patheon will convert API and Components into Product, and provide all supportive and related Manufacturing Services such as quality assurance
(for example quality controls, analytical testing, and stability programs), primary and secondary packaging, and any other related Manufacturing Services as agreed to between the parties. During the Launch Period, Patheon will manufacture One
Hundred (100%) percent of Client’s Product offered for sale by Client or its Affiliates (the “Initial Market Requirement”). Following the Launch Period, Client agrees that it will order from
Patheon the percentage of its manufacturing requirements in the Territory as set forth in the negotiated Product Agreement (the “Minimum Market Requirement”). 

 

	2.2	 Subcontracting. 

Patheon may, with the prior written consent of the Client, subcontract the Manufacturing Services under a Product Agreement to any of its
Affiliates, as agreed in the Product Agreement. Patheon will remain exclusively liable to Client for any breach of this Agreement or negligence by its Affiliates in the course of performing: (i) subcontracted Manufacturing Services under a
Product Agreement; or (ii) obligations under the Quality Agreement. Patheon may also arrange for non-Affiliate subcontractors to perform specific services arising under any Product Agreement with the
prior written consent of Client (“Third Party Subcontractors”). Patheon will be liable to Client for the breach of this Agreement or negligence of the Third Party Subcontractor or the failure by any Third Party
Subcontractor to perform any part of the subcontracted services. But Patheon’s liability for Third Party Subcontractors will remain subject to all limitations on Patheon’s liability as set out in this Agreement. Patheon will have no
liability arising from the performance of services by Third Party Subcontractors: (i) that are chosen by Client; (ii) that are suppliers or service providers not validated and utilized by Patheon prior to the date of this Agreement;
(iii) that are supplying materials or supplies required to perform the services; or (iv) to the extent that the Third Party Subcontractor is following the direct instructions of Client. 

 

	3.	 Client’s Obligations 

 

	3.1	 Payment. 

Subject to Appendix 2 of this Agreement, Client will pay Patheon the applicable Price in accordance with Sections 4 and 5. All cost items that
are not included in the Price (as specified in the applicable Product Agreement) are subject to additional fees to be paid by Client. 
  

	3.2	 Processing Instructions. 

Before the start of commercial manufacturing of Product under this Agreement, Client will give Patheon a copy of the Processing Instructions
or, together with Patheon, develop and implement such instructions, which must be accompanied by the applicable API, Component and finished product specifications (if applicable, precisely matching the specifications approved by the applicable
Regulatory Authority). If the Processing Instructions or accompanying documents received are amended or no longer reflect those currently approved by the Regulatory Authority, then Client will give Patheon a copy of the revised documents (if
applicable, precisely matching the revised specifications approved by the applicable Regulatory Authority). Upon acceptance of the revised Processing Instructions and accompanying documents, Patheon will give Client a signed and dated receipt
indicating Patheon’s acceptance. At Patheon’s request, Client will provide evidence of the executed original documents submitted by or on behalf of Client to the Regulatory Authority. 

  
 6 

	3.3	 API and Components. 

 

	 	(a)	 Client will, at its sole cost and expense, deliver the API and any Client-Supplied Components to the
Manufacturing Site DDP (Incoterms 2010). Client’s obligation with respect to such delivery will consist of obtaining the release of the API and any Client-Supplied Components from the applicable customs agency and Regulatory Authority. Unless
otherwise agreed in writing, Client or Client’s designated broker will be the “Importer” or “Importer of Record” (or equivalent, as understood under Applicable Laws) for API, Client-Supplied
Components, drug products and intermediates imported to the Manufacturing Site, and Client is responsible for compliance with Applicable Laws (and the cost of compliance) relating to that role. For API or Client-Supplied Components which may be
subject to import or export to or from the United States, Client agrees that its vendors and carriers will comply with applicable requirements of the U.S. Customs and Border Protection Service and the Customs Trade Partnership Against Terrorism.

  

	 	(b)	 Unless otherwise agreed in writing between the parties, the API and any Client-Supplied Components must be
delivered by the Client to the Manufacturing Site at least [***] before the scheduled manufacture date for Product covered by a Firm Order in sufficient quantity to enable Patheon to manufacture the agreed quantities of Product. Patheon reserves the
right to refuse to store any quantity of API in excess of the amount necessary for the Firm Order, at its sole discretion at any time but will use its commercially reasonable efforts to store such excess quantities. If Client fails to deliver the
API or Client-Supplied Components within the agreed time period and, after making commercially reasonable efforts, Patheon is unable to manufacture Product on the scheduled date because of the delay, the Firm Order will be considered cancelled by
Client and Section 5.1(e) will apply. 

  

	 	(c)	 Patheon will control the unloading of API and Client-Supplied Components arriving at the Manufacturing Site and
Client will comply and ensure that its carrier complies with all related directions of Patheon. The API and Client-Supplied Components will be held by Patheon on behalf of Client as set out in this Agreement. The API and Client-Supplied Components
will at all times remain the property of Client. Any API and Client-Supplied Components received by Patheon will only be used by Patheon to perform the Manufacturing Services. 

 

	 	(d)	 Client will ensure that: (i) all delivered API meets the specifications for that API and (ii) all
shipments of API are accompanied by the required documentation as specified in the applicable Quality Agreement. 

  

	 	(e)	 If Client asks Patheon to qualify an additional supplier for the API or any Component, the parties must agree
on the scope of work to be performed by Patheon and the additional fees to be paid by Client. For any API or any Component, this work at a minimum will include: (i) laboratory testing to confirm the API or Component meets existing
specifications; (ii) manufacture of an experimental batch of Product that will be placed on [***] accelerated stability; and (iii) manufacture of full-scale validation batches that will be placed on concurrent stability (one batch may be
the registration batch if manufactured at full scale). 

 Patheon will promptly advise Client if it encounters API or
Client-Supplied Component or Component supply problems, including delays or delivery of non-conforming API or Components from a Client designated additional supplier. The parties will cooperate to reduce or
eliminate any supply problems from these additional suppliers. If supply problems persist, Patheon may suspend the Manufacturing Services affected by the problems until it is satisfied that the Client has resolved the problems with its supplier or
appointed an alternative supplier. Client will qualify or certify (as appropriate) all Client designated additional suppliers on an annual basis at its expense and will provide Patheon with copies of the relevant annual reports. If Patheon agrees to
certify or qualify a Client designated additional supplier on behalf of Client, it will do so for an additional agreed-upon fee payable by Client. 

  
 7 

	3.4	 Packaging and Artwork. 

Client will be responsible for the cost of artwork development and approval of all artwork. Client will be responsible for changes to labels,
product inserts, and other packaging for the Product, including obtaining all required approvals. Client will be responsible for the cost of labelling obsolescence as contemplated in Section 5.2. Patheon’s name will not appear on the label
or anywhere else on the Product unless: (i) required by any Laws; or (ii) Patheon consents in writing to the use of its name. At least [***] prior to the Release Date of Product for which new or modified artwork is required, Client will
provide at no cost to Patheon and in accordance with the applicable specifications, final camera ready artwork for all packaging Components to be used in the manufacture of the Product. Client will be responsible for the costs associated with
complying with any and all regulatory requirements for the labelling and tracking of the manufactured Product, including product serialisation, product data transfer and anticounterfeiting requirements in the Territory. 

 

	4.	 Price and Price Adjustments 

 

	4.1	 First Year Pricing. 

The Price for each Product will be listed in Schedule A of a Product Agreement and may be adjusted under this Section 4. 

 

	4.2	 Annual Price Adjustments. 

Patheon may adjust the Price effective [***] as follows: 
  

	 	(a)	 Inflation. Patheon may adjust the Price for inflation in accordance with Appendix 4.

  

	 	(b)	 Currency Fluctuations. If the parties agree in a Product Agreement to invoice in a currency other than
the Local Currency for the Manufacturing Site, Patheon will adjust the Price to reflect currency fluctuations. The adjustment will be calculated in accordance with Appendix 4 after all other annual Price adjustments under this Section 4.2 have
been made. 

  

	 	(c)	 Pricing Basis. Client and Patheon acknowledge and agree that the Price in any Year is to be mutually
negotiated and agreed upon. The factors to consider include the applicable Minimum Market Requirement, Annual Volume, and Minimum Order Quantity for that Year. Patheon may adjust the Price if it reasonably concludes, or is notified by Client, that
the Minimum Market Requirement, Annual Volume or Minimum Order Quantity will not be ordered in a Year. 

  

	 	(d)	 Tier Pricing. If the Pricing is divided into Annual Volume tiers, unless otherwise agreed in a Product
Agreement, Client will be invoiced during the Year based at the lowest volume tier. Within [***] after the end of each Year and on termination of the Product Agreement, Patheon will send Client a reconciliation of the actual volume of Product
ordered by Client during the Year at the actual applicable Pricing tiers. If the reconciliation shows an overpayment, Patheon will issue a credit to Client for the amount for the amount of the overpayment within [***] after the end of the Year or
will reimburse the overpayment within [***] after the end of such Year or of such termination. The parties will use their commercially reasonable efforts and work together in good faith to resolve any disagreement over the reconciliation.

  
 8 

 For all Price adjustments under this Section 4.2, Patheon will deliver to Client on or
about [***] (unless otherwise agreed in writing) a letter stating the adjusted Pricing under a Product Agreement to be effective for Product to be delivered on or after [***] including any Firm Orders accepted by Patheon before that date. 

 

	4.3	 Price Adjustments at any Time. 

The Prices may be adjusted by Patheon at any time upon written notice to Client as follows: 

 

	 	(a)	 Extraordinary Increases in Component Costs. If the cost of a Component increases cumulatively by at
least [***] percent since the last annual adjustment as a result of market factors outside of Patheon’s control, then Patheon will be entitled to adjust the Price proportionately and as otherwise agreed in the Product Agreement. The revised
Price will become effective with [***]. For a Price adjustment under this Section 4.3(a), Patheon will deliver to Client a revised Schedule A to the Product Agreement. 

 

	 	(b)	 Changes. The scope of the Manufacturing Services is set by the agreed Processing Instructions, the
Regulatory Approvals, the Quality Agreement and any assumptions, inclusions, exclusions and other parameters set out in the applicable Product Agreement. Changes to the scope of the Manufacturing Services and related changes to the Price must be
agreed in writing by the parties (using a “Change of Scope” agreement, or similar, setting out the agreed activities and costs of implementation) and are subject to the change control provisions of the Quality Agreement.
Where Patheon requests a change to the Manufacturing Services, the change will be implemented following written approval of Client, which Client will not unreasonably withhold, condition or delay. 

 

	5.	 Purchasing Product 

 

	5.1	 Orders and Forecasts. 

 

	 	(a)	 Long Term Forecast. On or before June 1 of each Year, Client will give Patheon a non-binding written forecast of Client’s volume requirements for the Product for each of the next [***] (“Long Term Forecast”). If Patheon foresees any capacity constraint affecting any portion
of the Long Term Forecast, it will notify Client within [***] following receipt of the Long Term Forecast, and the parties will agree on a revised Long Term Forecast within Patheon’s expected capacity. Each updated Long Term Forecast supersedes
all previous Long Term Forecasts. All forecasts under this Agreement shall specify the number of Batches or units, as applicable. 

  

	 	(b)	 Rolling Forecast. Before each Product Agreement is executed, Client will give Patheon a written forecast
of the volume of Product that Client expects to order in each of the next [***] (the “Rolling Forecast”). Client will use commercially reasonable efforts to make the Rolling Forecast consistent with the most recent Long Term
Forecast. Client will provide an updated Rolling Forecast: (i) on or before the [***] of each month; and (ii) if at any time it determines that the total forecast volumes estimated in the most recent Rolling Forecast have changed by more
than [***] percent. Each updated Rolling Forecast supersedes all previous Rolling Forecasts. 

  
 9 

	 	(c)	 Orders. On or before the [***] of each month, Client will issue a new purchase order for any required
Product. Each purchase order must meet the Minimum Order Quantity as noted in the applicable Product Agreement and specify the purchase order number, quantities by Product type, and requested release dates for the Product (which must occur at least
[***] after the first day of the next month). 

  

	 	(d)	 Acceptance of Purchase Orders. To the extent that a purchase order covers Product that is forecast in
the Rolling Forecast, Patheon will accept the purchase order by sending an acknowledgement to Client, including the confirmed Release Dates. Subject to Section 5.1(f), if Patheon fails to acknowledge receipt of a purchase order within [***],
the purchase order will be considered accepted by Patheon. An accepted purchase order will be binding on the parties (a “Firm Order”), except that either party may request to change any Release Date beyond [***] after the
first day of the next month. The parties will negotiate in good faith and agree on any requested alternative release date. Neither party may unreasonably reject an alternative release date requested under this Section 5.1(d), but, if the
parties cannot agree, the original Release Date confirmed by Patheon will apply. 

  

	 	(e)	 Cancellation or Postponement. Patheon will determine the manufacturing schedule of all Product covered
by Firm Orders which shall be consistent with Client’s delivery requirements. If Client cancels or reduces a Firm Order, or wishes to postpone the applicable Release Date (subject to Section 5.1(d)), Client will remain liable to pay
Patheon [***] percent of the Price for the Firm Order. 

  

	 	(f)	 Capacity Reservation. On July 1st in the last Year of the Launch Period, Patheon will use the Rolling
Forecast to reserve its manufacturing capacity in the next Year for Product. 

 In all other cases, by reference to the
Rolling Forecast applicable at June 1 of each Year, the relevant forecast for the Year being the “Yearly Forecast Volume”. 

At the end of each Year after the Launch Period, if the aggregate actual Batches ordered by Client with a confirmed Release Date within the
Year, taking into account any Product paid for but not ordered, (“Actual Yearly Volume”) is less than [***] of the Yearly Forecast Volume, then Patheon may invoice and Client will pay Patheon the Conversion Fee portion of the Price
for the shortfall of Product below the tolerance during the Year in an amount calculated as follows: 
 Amount Due to Patheon 

= ((Yearly Forecast Volume x [***]) — Actual Yearly Volume’) x Conversion Price for the Product 

If the quantity of Product requested by Client in a Year (in purchase orders received by Patheon) exceeds the Yearly Forecast Volume for that
Year, Patheon will use commercially reasonable efforts to supply the additional Product volumes. Patheon will not be considered to have accepted any purchase order for additional Product volumes without written confirmation. 

 

	 	(g)	 Controlled Substance Quota Requirements (if applicable). Client will give Patheon the information set
out below for obtaining any required DEA or equivalent agency quotas (“Quota”) needed to perform the Manufacturing Services. Patheon will be responsible for routine management of Quota information in accordance with
Applicable Laws. The parties will cooperate to communicate the information and to assist each other in Regulatory Authority information requirements related to the Product as follows: (i) by April 1 of each Year for the applicable Product,
Client will provide to Patheon the next 

  
 10 

	 	
Year’s annual Quota requirements for the Product; (ii) by [***], Client will provide to Patheon any changes to the next Year’s Quota requirements; (iii) Client will pro-actively communicate any changes to the Quota requirements for the then-current Year in sufficient time to allow Patheon to file and finalize Regulatory Authority filings supporting the changes; (iv) upon
Patheon receiving the necessary forecast information from Client in order to request additional Quota, Patheon will submit to the applicable Regulatory Authority, on a timely basis, all filings necessary to obtain Quotas for API and will use
commercially reasonable efforts to secure sufficient Quota from the applicable Regulatory Authority so as to achieve Release Dates for Product as set out in applicable purchase orders and forecasts submitted to Patheon by Client or its designee; and
(v) Patheon will not be responsible for any Regulatory Authority’s refusal or failure to grant sufficient Quota for reasons beyond the reasonable control of Patheon (including where Client fails to provide the required information in
accordance with this Section 5.1(g)). 

  

	5.2	 Obsolete Stock. 

 

	 	(a)	 Client understands and acknowledges that Patheon will rely on purchase orders, Firm Orders, the Long Term
Forecast and the Rolling Forecast in ordering the Components (other than Client-Supplied Components) required to meet anticipated Firm Orders. Patheon may purchase the Components in sufficient volumes, and reasonably in advance of the expected use
of the Component (taking into account lead times), to meet the production requirements for Products covered by anticipated Firm Orders or for the Rolling Forecast to meet the production requirements of any other amounts agreed to by the parties.

  

	 	(b)	 For Components ordered by Patheon in relation to Firm Orders or under Section (a) that are not used in the
Manufacturing Services within [***] after the forecasted month for which the purchases have been made due to actual orders being less than the Firm Orders or Rolling Forecasts, or if the Components have expired or are rendered obsolete due to
Client- required changes in any Processing Instructions, GMP, or artwork, or due to changes in Applicable Laws during the period (collectively, “Obsolete Stock”). Client shall either (i) at Client’s cost (plus a [***]
handling fee) pick up from Patheon’s Manufacturing Site all obsolete stock or (ii) reimburse Patheon for the cost of obsolete stock which reimbursement will include Patheon’s cost to purchase and destroy the Obsolete Stock (plus a
[***] percent handling fee). Client shall elect either (i) or (ii) within [***] of receipt of written notice from Patheon identifying the Obsolete Stock. If any non-expired Components are used in Products
subsequently manufactured for Client or in third party products manufactured by Patheon, Client will receive credit for any costs of those Components previously paid to Patheon by Client. 

 

	5.3	 Storage. 

If: (i) Client fails to take possession or arrange for the destruction of Obsolete Stock within [***] of receipt of written notice from
Patheon identifying the Obsolete Stock; (ii) any equipment (other than existing Patheon equipment) is stored at the Manufacturing Site at any time prior to its use in the Manufacturing Services; or (iii) Product is not collected by Client
within [***] of the Release Date notified by Patheon, Client will pay Patheon USD [***] per pallet, per month after that for storing the Obsolete Stock, equipment or Product. Storage fees for Obsolete Stock or Product which contain controlled
substances or require refrigeration will be charged at USD [***] per pallet per month. Storage fees are subject to a one (1) pallet minimum charge per month. Patheon may ship Product held by it longer than [***] to Client at Client’s
expense on [***] written notice to Client. If Patheon is unable to store any material due to capacity constraints, Patheon may use an Affiliate or qualified third party to store (outside the Manufacturing Site) any material under this Agreement.
After the limited storage periods stated above, Client will assume all risk of loss or damage to materials and Client will be responsible for having appropriate insurance coverage in place for this risk. 

  
 11 

	5.4	 Invoices and Payment. 

For shipments of Product, Patheon will issue invoices to Client on or after the Release Date of the Product. Otherwise, Patheon will issue
invoices for Manufacturing Services on completion or as agreed in the Product Agreement. Patheon will also submit to Client, with each shipment of Product, a duplicate copy of the invoice covering the shipment. Invoices will be sent by email to the
email address given by Client to Patheon in writing. Each invoice will, to the extent applicable, identify Client’s Manufacturing Services purchase order number, Product numbers, names and quantities, unit price, freight charges, and the total
amount to be paid by Client. Client will pay all undisputed invoices within [***] of the date of the invoice. If any portion of an invoice is disputed, Client will pay Patheon for the undisputed amount and the parties will use good faith efforts to
reconcile the disputed amount as soon as practicable. Interest on undisputed past due accounts will accrue at [***] per month. Patheon may, on giving [***] notice to Client, suspend all Manufacturing Services, including release and shipment of
Product, until all undisputed past due invoices have been paid in full. Patheon will have no liability to Client for losses caused by this suspension, including without limitation, losses due to delayed Product delivery or Product shortages. 

 

	5.5	 Delivery and Shipping. 

Delivery of Product and any other materials will be made EXW (Incoterms 2010) from Patheon’s Manufacturing Site unless otherwise agreed in
a Product Agreement. Subject to Section 8.3, risk of loss or of damage to Product will remain with Patheon until Patheon loads the Product onto the carrier’s vehicle for shipment at the shipping point at which time risk of loss or damage
will transfer to Client. But if Client fails to collect Product within [***] after it has been released for shipment by Patheon, Client will assume all risk of loss or damage to the released Product. Patheon may, in accordance with Client’s
instructions and as agent for Client, at Client’s risk, arrange for shipping (to Client or any third party nominated by Client) to be paid by Client. Client will arrange for insurance and will select the freight carrier used by Patheon to ship
Product and may monitor Patheon’s shipping and freight activity under this Agreement. 
  

	6.	 Product Claims and Recalls 

 

	6.1	 Product Claims. 

 

	 	(a)	 Rejection. Client may reject any manufactured Product that it reasonably considers (by reference to the
results of the agreed release testing) to be deficient based on: (i) documentation provided by Patheon, (ii) Client’s own inspection, (iii) testing of delivered Product or (iv) is not manufactured in accordance with the
Processing Instructions, Product Agreement or this Agreement. 

  

	 	(b)	 Product Claims. 

 

	 	(i)	 Client may claim a remedy (a “Product Claim”) for any portion of any batch of Product for
which Patheon did not perform the Manufacturing Services in accordance with the agreed Processing Instructions, cGMPs, or Applicable Laws (“Deficient Product”). Client will inspect Product manufactured by Patheon, or batch
documentation provided by Patheon, upon receipt and will give Patheon written notice of all Product Claims within [***] after receipt (or, in the case of any deficiency not susceptible to discovery upon receipt, within [***] after discovery by
Client, but not after the expiration date of the Product). If Client fails to provide a Product Claim within the applicable [***] period, then the Product will be considered to have been accepted by Client on the [***]. Patheon will have no
liability for any deficiency for which it has not received notice within the applicable [***] period. 

  
 12 

	 	(ii)	 This Section 6 sets out the only liability of Patheon for Deficient Products. Patheon will provide a
remedy for Product Claims as specified in Section 10.2, but Patheon will have no obligation for any Product Claims to the extent the Deficient Product was caused by: (i) deficiencies in the Processing Instructions, specifications, the
safety, efficacy, or marketability of the Product or its distribution; (ii) a defect in the API or an incorporated Component that was not reasonably discoverable by Patheon using the test methods set out in the Processing Instructions;
(iii) actions of Client or third parties occurring after the Product is delivered by Patheon; (iv) packaging design or labelling defects or omissions for which Patheon has no responsibility; (v) any unascertainable reason despite
Patheon having performed the Manufacturing Services in accordance with the Processing Instructions, cGMPs, and Applicable Laws; or (v) any other breach by Client of its obligations under this Agreement that resulted in a Deficient Product. If
after a full investigation as set out in the Quality Agreement and this Section 6.1 (b)(ii), it is determined that Patheon manufactured Product in accordance with the agreed Processing Instructions, but a batch or portion of batch of Product is
not released, Client will pay Patheon the Price for the Product. Patheon’s only liability for API loss is set out in Appendix 3. 

  

	 	(c)	 Determination of Deficiency. Upon receipt of a Product Claim, Patheon will have [***] to advise Client
by notice in writing if it disagrees with the contents of the Product Claim. If the parties fail to agree within [***] after Patheon’s notice to Client as to whether any Product identified in the Product Claim is Deficient Product, the parties
will investigate the matter in accordance with the Quality Agreement. If, after joint testing or investigation has been performed, the parties still cannot agree on the root cause, the provisions of Appendix 2 will apply and, after the required
negotiation, the dispute will be handled as a Technical Dispute. 

  

	 	(d)	 Shortages and Price Disputes. Claims for shortages in the amount of Product shipped by Patheon or a
Price dispute will be dealt with by reasonable agreement of the parties. Any claim for a shortage or a Price dispute will be considered waived by Client if it has not been presented within [***] of the date of the relevant invoice.

  

	6.2	 Product Recalls and Returns. 

 

	 	(a)	 Records and Notice. The parties will each maintain records necessary to permit a Recall of any Product
delivered to Client or customers of Client. Each party will promptly notify the other of any information which might affect the marketability, safety or effectiveness of the Product or which might result in the Recall or seizure of the Product in
accordance with the Quality Agreement. Upon receiving this notice or upon this discovery, each party will stop making any further shipments of any Product in its possession or control until a decision has been made whether a Recall or some other
corrective action is necessary. The decision to initiate a Recall or to take some other corrective action, if any, will be made and implemented by Client. “Recall” will mean any action: (i) by Client to recover title to
or possession of quantities of the Product sold or shipped to third parties (including, without limitation, the voluntary withdrawal of Product from the market); (ii) by any Regulatory Authority to detain or destroy any of the Product; or
(iii) by either party to refrain from selling or shipping quantities of the Product to third parties which would be subject to a Recall if sold or shipped. 

  
 13 

	 	(b)	 Recalls. If: (i) any Regulatory Authority issues a directive, order or, following the issuance of a
safety warning or alert about a Product, a written request that any Product be Recalled; (ii) a court of competent jurisdiction orders a Recall; or (iii) Client determines that any Product should be Recalled or that a “Dear
Doctor” letter is required relating the restrictions on the use of any Product, then Patheon will co-operate as reasonably required by Client, having regard to all Applicable Laws.

  

	 	(c)	 Recalled Product. To the extent that a Recall results from, or arises from Deficient Product, Patheon
will be responsible for all reasonable documented out-of-pocket expenses of the Recall and will replace the Deficient Product with replacement Products as per
Section 10. In all other circumstances, Recalls, returns, or other corrective actions will be made at Client’s cost and expense unless caused by the negligent action or inaction of Patheon. Patheon’s only liability for API loss is set
out in Appendix 3. 

  

	6.3	 Disposition of Deficient Product. 

Client will not dispose of any damaged, returned, or Deficient Product for which it intends to assert a Product Claim against Patheon without
Patheon’s prior written authorization to do so. Patheon may instruct Client to return the Products to Patheon. Patheon will bear the cost of return and disposition of any Deficient Products. In all other circumstances, Client will bear the cost
of return and disposition, including all applicable fees for Manufacturing Services. 
  

	7.	 Co-operation and Regulatory Affairs 

 

	7.1	 Governance. 

Each party will without delay upon execution of this Agreement or a Product Agreement appoint one of its employees to be a relationship manager
responsible for liaison between the parties. The relationship managers will meet on a frequency agreed to between the parties to review the current status of the business relationship, including review of key performance indicators such as API
delivery, on-time delivery, right first time, attainment of the Minimum Market Requirement and manage any issues that have arisen. 
  

	7.2	 Governmental Agencies. 

Subject to any restrictions in the Quality Agreement, either party may communicate with any Regulatory Authority responsible for granting
Regulatory Approval for the Product and any other relevant Authority regarding the Product if, in the opinion of that party’s counsel, the communication is necessary to comply with the terms of this Agreement or the requirements of the
Authority or Applicable Laws. Otherwise, the parties will consult each other in relation to regulatory communications relating to the Product in accordance with the Quality Agreement. 

  
 14 

	7.3	 Records. 

Patheon will keep records of the manufacture, testing, and shipping of the Product, and retain samples of the Product as are necessary to
comply with all manufacturing regulatory requirements applicable to Patheon, Applicable Laws, cGMP and the Quality Agreement. Copies of the records and samples will be retained as and for the period specified in the Quality Agreement or longer as
may be required by any Applicable Law. Patheon reserves the right to destroy or return to Client, at Client’s sole expense, any document or samples for which the retention period has expired if Client fails to arrange for destruction or return
within [***] of receipt of written notice from Patheon. 
  

	7.4	 Audits. 

Subject to the limits agreed in the Quality Agreement, Patheon will give Client access at mutually agreed times to the areas of the
Manufacturing Site in which the Product is manufactured, stored, handled, or shipped to permit Client to verify that the Manufacturing Services are being performed in accordance with the specifications, Product Agreement, cGMPs, and Applicable Laws.
If Client wishes to audit Patheon beyond the agreed limits, except where the audit is required due to Patheon’s breach, Client will pay to Patheon a fee of USD [***] for each additional audit day and USD [***] per audit day for each additional
auditor. Under no circumstances will: (a) Client have a right of access to Patheon’s financial record; or (b) any Patheon Competitor be permitted access to the Manufacturing Site. 

 

	7.5	 Regulatory Filings. 

 

	 	(a)	 Regulatory Authority Documentation. Client will provide copies of all relevant documents relating to
Regulatory Authority approval for the commercial manufacture, distribution and sale of the Product (“Regulatory Approval”) to Patheon on request and as required under the Quality Agreement. Patheon will review and verify the
accuracy of these documents in accordance with the Quality Agreement. Client is not entitled to submit Regulatory Approvals referring to Patheon or its Affiliates or the Services until approved by Patheon. 

 

	 	(b)	 Deficiencies. If, in Patheon’s sole discretion, acting reasonably, Patheon determines that any
regulatory information given by Client is inaccurate or deficient in any manner whatsoever (the “Deficiencies”), Patheon will notify Client in writing of the Deficiencies. The parties will work together to have the Deficiencies
resolved prior to the date of filing of the relevant application and in any event before any pre-approval inspection or before the Product is placed on the market if a
pre-approval inspection is not performed. 

  

	 	(c)	 Inspection by Regulatory Authorities. If Client does not give Patheon the documents requested under this
Section 7.5 or the Quality Agreement within the time specified and if Patheon reasonably believes that Patheon’s standing with a Regulatory Authority may be jeopardized, Patheon may, in its sole discretion, delay or postpone any inspection
by the Regulatory Authority until Patheon has reviewed the requested documents and is satisfied with their contents. Client’s breach of this requirement will be considered a material breach of this Agreement. 

 

	 	(d)	 Pharmacovigilance. Client will be responsible, at its expense, for all pharmacovigilance obligations for
the Product in accordance with Applicable Laws and the monitoring and management of post-marketing complaints and queries at its cost (including, without limitation, the cost of assistance required of Patheon under the Quality Agreement). Unless
required by Applicable Law, neither party will be obliged to exchange with the other party any information or data which it compiles in carrying out pharmacovigilance obligations or activities. 

  
 15 

	 	(e)	 No Patheon Responsibility. Except as otherwise agreed in the Quality Agreement, Patheon will not assume
any responsibility for: (a) the submission, accuracy or cost of any application for Regulatory Approval or related documentation (or the success of those applications); (b) any activity that is required by Applicable Laws for Regulatory
Approval (including pharmacovigilance and complaints handling, and preparation and submission of any regular quality or other update); or (c) any dealings with the relevant Regulatory Authority on behalf of Client for Regulatory Approval. If a
Regulatory Authority, or other governmental body, requires Patheon to incur fees, costs or activities in relation to the Products which Patheon considers unexpected and extraordinary, then Patheon will notify Client in writing and the parties will
discuss in good faith appropriate mutually acceptable actions, including fee/cost sharing, or termination of all or any part of this Agreement or a Product Agreement. Patheon will be not be obliged to undertake these activities or to pay for the
fees or costs until the parties reach agreement on scope and fees for Patheon’s assistance. 

  

	7.6	 Release. 

The parties agree that the release of the Products for sale or distribution under the applicable marketing approval for the Product will not by
itself indicate compliance by Patheon with its obligations relating to the Manufacturing Services or the applicable Product Agreement. Nothing in this Agreement will remove or limit the authority of the relevant quality function (as specified by the
Quality Agreement) to determine whether the Product will be released for sale or distribution. 
  

	7.7	 Withdrawal on Completion. 

No later than [***] following completion or permanent cessation of the Manufacturing Services at the applicable Manufacturing Site, Client
will: (a) ensure that any regulatory filings relating to the Product are withdrawn or amended to remove all references to the Manufacturing Site and, as applicable, Patheon or its Affiliates and their facilities (except in an historic context);
and (b) provide to Patheon written confirmation of its compliance with this Section 7.7. If this time is not sufficient to meet the requirements of certain Regulatory Authorities, despite Client’s best efforts, then Patheon shall
agree to reasonably extend the period based on the written reassurances of Client. 
  

	8.	 Term and Termination 

 

	8.1	 Initial Term. 

This Agreement will become effective as of the Effective Date and will continue until December 31 2025 (the “Initial
Term”), unless terminated earlier by one of the parties. This Agreement will automatically renew after the Initial Term if there is a Product Agreement in effect and will terminate co-terminus
with the last Product Agreement to expire unless otherwise agreed by the Parties. In any event, the legal terms and conditions of this Agreement will continue to govern any Product Agreement in effect. Each Product Agreement will have an initial
term from the Effective Date of the Product Agreement until the date agreed to by the Parties (each, an “Initial Product Term”). 

 

	8.2	 Termination for Cause. 

 

	 	(a)	 Either party may terminate this Agreement or a Product Agreement upon written notice where the other party has
failed to remedy a material breach of this Agreement or the Product Agreement within [***] (the “Remediation Period”) following receipt of a written notice of the breach from the aggrieved party that expressly states that it
is a notice under this Section 8.2(a) (a “Breach Notice”). In the event of any conflict, the terms of this Agreement will supercede the terms and conditions of the Product Agreement unless

  
 16 

	 	
otherwise specifically agreed to in writing. The aggrieved party’s right to terminate this Agreement or a Product Agreement under this Section 8.2(a) may only be exercised for a period
of [***] following the expiry of the Remediation Period (where the breach has not been remedied) and if the termination right is not exercised during this period then the aggrieved party will be considered to have waived the breach described in the
Breach Notice and if timely exercised this Agreement or a Product Agreement shall accordingly be terminated and be declared null and void except for those provisions which survive in accordance with their terms. The right to terminate a Product
Agreement under this Section 8.2(a) does not extend to any other Product Agreements where there has been no material breach of those other Product Agreements. Notwithstanding anything to the contrary herein, in the event Patheon is not able to
timely manufacture and deliver the Product in accordance with Section 2.1 due to Patheon’s negligence or failure to perform under the terms hereof then the Client shall have the right , upon written notice to Patheon, to secure alternative
manufacturing services. Client’s rights in this Section 8.2(a) shall continue so long as Patheon is unable to comply with the terms of Section 2.1 due to its negligence or failure to perform under this Agreement. 

 

	 	(b)	 Either party may immediately terminate this Agreement or a Product Agreement upon written notice to the other
party if: (i) the other party is declared insolvent or bankrupt by a court of competent jurisdiction; (ii) a voluntary petition of bankruptcy or insolvency is filed in any court of competent jurisdiction by the other party; or
(iii) this Agreement or a Product Agreement is assigned by the other party for the benefit of creditors. 

  

	 	(c)	 Client may terminate a Product Agreement upon [***] prior written notice if any Authority takes any action, or
raises any objection, that permanently prevents Client from selling the Product in the Territory. 

  

	 	(d)	 Client may terminate a Product Agreement upon [***] prior written notice if it intends to no longer order
Manufacturing Services for a Product due to the Product’s discontinuance in the market. 

  

	 	(e)	 Patheon may terminate this Agreement or any Product Agreement upon [***] prior written notice if Client assigns
under Section 13.4 any of its rights under this Agreement or a Product Agreement to an assignee that, in the reasonable opinion of Patheon, is: (i) unlikely to be able to meet the obligations of this Agreement or a Product Agreement;
(ii) is as of the date of the assignment a Patheon Competitor as supported by reasonable evidence; or (iii) an entity with whom Patheon has had prior unsatisfactory business relations (as supported by reasonable evidence of late or unpaid
invoices or material disputes). 

  

	 	(f)	 Patheon may terminate this Agreement or any Product Agreement if payment in full of overdue, undisputed
invoices is not received within [***] following the date of suspension of Manufacturing Services by Patheon under Section 5.4. 

  

	 	(g)	 If Client forecasts zero volume for [***] during the term of a Product Agreement (excluding regulatory issues
or the registration period), then Patheon may terminate the Product Agreement by providing [***] prior written notice to Client. Within that [***] period, Client may either: (i) withdraw the zero forecast and
re-submit a reasonable volume forecast, after which Patheon will withdraw the termination notice or (ii) negotiate other terms and conditions on which the Product Agreement will remain in effect.

  
 17 

	8.3	 Obligations on Termination. 

If a Product Agreement is completed, expires, or is terminated in whole or in part for any reason, then: 

 

	 	(a)	 Client will take delivery of and pay for all undelivered Products that are manufactured or packaged in
accordance with this Agreement under a Firm Order, at the Price in effect at the time the Firm Order was released; 

  

	 	(b)	 Client will purchase all Inventory that was purchased (or will be purchased under existing unfulfilled orders
for Components), maintained or produced by Patheon in contemplation of filling Firm Orders or in accordance with Section 5.2, at Patheon’s cost (including all costs incurred by Patheon for the purchase, handling, and processing of the
Inventory); 

  

	 	(c)	 Client, at its own expense, will remove from the Manufacturing Site, within [***] following the completion,
termination, or expiration of the Product Agreement, all unused API and Client-Supplied Components, all applicable Inventory (whether current or obsolete), supplies, undelivered Product, chattels, equipment or other moveable property owned by
Client, related to the Agreement and located at the Manufacturing Site or that is otherwise under Patheon’s care and control (“Client Property”). If Client fails to remove Client Property within the [***] period, which may be
extended by the Client for unforeseen circumstances, for up to an additional [***] period, Client will then pay Patheon [***] per pallet, per month, one pallet minimum (except that Client will pay [***] per pallet, per month, one pallet minimum, for
any of Client Property that contains controlled substances, requires refrigeration or other special storage requirements) after that for storing Client Property and will assume any third party storage charges invoiced to Patheon regarding Client
Property (which Patheon may incur at its discretion). Patheon may ship Client Property to Client or to an external warehouse at Client’s risk and expense. Patheon will invoice Client for these storage charges as set out in Section 5.3 of
this Agreement. If Client fails to remove Client Property within [***] following the completion, termination, or expiration of the Product Agreement, which may be extended by the Client for unforeseen circumstances, for up to an additional [***]
period, Client will assume all risk of loss or damage to the stored Client Property and it will be Client’s responsibility to have appropriate insurance coverage in place for this risk. If Client asks Patheon to destroy any Client Property,
Client will be responsible for the cost of destruction; and 

  

	 	(d)	 any completion, termination or expiration of this Agreement or a Product Agreement will not affect any prior
outstanding obligations or undisputed payments due nor will it prejudice any other remedies that the parties may have under this Agreement or a Product Agreement or any related Capital Equipment Agreement. Completion, termination or expiration of
this Agreement or of a Product Agreement for any reason will not affect the obligations and responsibilities of the parties under Sections 5.1(e), 5.1(f), 5.4, 5.5, 8.3, 10, 11, 12, 13.14, 13.15 and 13.16, all of which shall survive any completion,
termination or expiration of this Agreement of a Product Agreement, as well as any other provisions that are by implication or otherwise intended to survive any completion, termination or expiration. Where Patheon has agreed to provide stability
services beyond the final supply of Product, the relevant provisions of this Agreement will survive for the agreed duration of those stability services. 

  
 18 

	8.4	 Technology Transfer. 

Following termination of a Product Agreement for any reason, or at Client’s request within [***] before the end of the term of a Product
Agreement, Patheon will provide assistance to transfer all of Client’s manufacturing process, know-how and analytical testing methodology for the Product to Client (“Technology Transfer”) to
assist Client to manufacture the Product. Patheon will also disclose to Client any Patheon Intellectual Property that is required or helpful to manufacture the Product. Patheon will, upon request of Client, prepare a written proposal to perform the
Technology Transfer. Client will pay the mutually agreed reasonable fee for the Technology Transfer performed by Patheon. 
  

	9.	 Representations, Warranties and Covenants 

 

	9.1	 Authority. 

Each party covenants, represents, and warrants that it has the full right and authority to enter into this Agreement and inter-related
agreements and that it is not aware of any impediment that would inhibit its ability to perform its obligations under this Agreement or any inter-related agreements. 
  

	9.2	 Client Warranties. 

 

	 	(a)	 Non-lnfrinqement. Client covenants, represents, and warrants
that: 

  

	 	(i)	 the Processing Instructions and specifications for the Product are its or its Affiliate’s property and
that Client may lawfully disclose the Processing Instructions and specifications to Patheon for use in accordance with this Agreement; 

  

	 	(ii)	 any Client Intellectual Property used by Patheon in performing the Manufacturing Services: (A) is
Client’s or its Affiliate’s unencumbered property, (B) may be lawfully used as directed by Client and agreed in this Agreement and (C) to the Client’s knowledge, does not infringe any Third Party Rights;

  

	 	(iii)	 the performance of the Manufacturing Services by Patheon or the use or other disposition of any Product by
Patheon as may be required to perform its obligations under this Agreement or any Product Agreement does not, to the Client’s knowledge, infringe any Third Party Rights; and (iv) to the Client’s knowledge, there are no actions or
other legal proceedings involving Client or its Affiliates that concerns the infringement of Third Party Rights related to any of the Processing Instructions or specifications, or any of the API or Client-Supplied Components, or the sale, use, or
other disposition of Product made in accordance with the Processing Instructions. 

  

	 	(b)	 Quality and Compliance. Client covenants, represents, and warrants that: 

 

	 	(i)	 the Processing Instructions and specifications for the Product conforms to all applicable cGMPs and Applicable
Laws; 

  

	 	(ii)	 the Product, if labelled and manufactured in accordance with the Processing Instructions and in compliance with
applicable cGMPs and Applicable Laws: (i) may be lawfully sold and distributed in every jurisdiction in which Client markets the Product, (ii) will be fit for the purpose intended and (iii) will be safe for human consumption; and
(iii) on receipt by Patheon, the API will conform to the specifications for the API that Client has given to Patheon and that the API will be adequately contained, packaged, and labelled in accordance with Applicable Laws and will conform to
the affirmations of fact on the container. 

  
 19 

	9.3	 Patheon Warranties. 

Patheon covenants, represents, and warrants that: 
  

	 	(a)	 it will perform the Manufacturing Services with experienced, trained employees and qualified subcontractors and
in accordance with this Agreement, a Quality Agreement, a Product Agreement, the Processing Instructions, cGMPs, and Applicable Laws; 

  

	 	(b)	 any Patheon Intellectual Property used by Patheon to perform the Manufacturing Services: (i) is
Patheon’s or its Affiliate’s unencumbered property, (ii) may be lawfully used by Patheon, and (iii) to Patheon’s knowledge, does not infringe and will not infringe any Third Party Rights; 

 

	 	(c)	 it will not in the performance of its obligations under this Agreement use the services of any person it knows
is debarred or suspended under 21 U.S.C. §335(a) or (b); and 

  

	 	(d)	 it does not currently have, and it will not hire, as an officer or an employee any person whom it knows has
been convicted of a felony under the laws of the United States for conduct relating to the regulation of any drug product under the United States Federal Food, Drug, and Cosmetic Act. 

 

	 	(e)	 Patheon shall perform all of its obligations under this Agreement in full compliance with all Applicable Laws
in the Territory. Patheon shall hold during the Term of this Agreement all licenses, permits and similar authorizations required by any Regulatory Authority in the Territory for Patheon to perform its obligations under this Agreement.

  

	 	(f)	 The Product furnished by Patheon to Client under this Agreement: 

 

	 	(i)	 will perform the Manufacturing Services in accordance with the agreed Processing Instructions, cGMPs, or
Applicable Laws and shall be manufactured, packaged, labelled, handled, stored and shipped in compliance with all applicable Laws including the agreed Processing Instructions, cGMPs, and in accordance with the Quality Agreement; and

  

	 	(ii)	 shall only contain Product material that has been used, handled, or stored in accordance with the
specifications, all applicable Laws and the Quality Agreements; 

  

	9.4	 Permits. 

  

	 	(a)	 Client will be solely responsible for obtaining or maintaining, on a timely basis, any permits or other
regulatory approvals for the Product, Processing Instructions or specifications, including, without limitation, all marketing and post-marketing approvals, and any specific approvals referred to in the Quality Agreement. 

 

	 	(b)	 Patheon will maintain at all relevant times when performing the Manufacturing Services during the Term of this
Agreement, all required governmental permits, licenses, approval, and authorities. 

  
 20 

	9.5	 No Warranty. 

PATHEON MAKES NO WARRANTY OR CONDITION OF ANY KIND, EITHER EXPRESSED OR IMPLIED, BY FACT OR LAW, OTHER THAN THOSE EXPRESSLY SET OUT IN THIS
AGREEMENT. PATHEON MAKES NO WARRANTY OR CONDITION OF FITNESS FOR A PARTICULAR PURPOSE NOR ANY WARRANTY OR CONDITION OF MERCHANTABILITY FOR THE PRODUCT. 
  

	10.	 Liability and Remedies 

 

	10.1	 Consequential and Other Damages. 

Under no circumstances whatsoever will either party be liable to the other in contract, tort, negligence, indemnity, breach of statutory duty,
or otherwise for: (i) any (direct or indirect) delay, penalty, loss of profits, of anticipated savings, of business, of goodwill, or of use of the Product or costs of any substitute services; or (ii) any reliance damages, including but not
limited to costs or expenditures incurred to evaluate the viability of entering into this Agreement or to prepare for performance under this Agreement; or (iii) for any other liability, damage, costs, penalty, or expense of any kind incurred by
the other party of an indirect or consequential nature, regardless of any notice of the possibility of these damages. 
  

	10.2	 Limitation of Liability. 

 

	 	(a)	 Remedies for Deficient Product. If Client makes a Product Claim under Section 6.1 and the parties
agree the Product is a Deficient Product, or the Product is determined to be a Deficient Product under Section 6, Patheon will promptly, at Client’s election, either: 

 

	 	(i)	 replace the Product at Patheon’s cost (after which Patheon may invoice for the replacement) if Patheon is
able to manufacture the replacement Product at the Manufacturing Site and contingent upon the receipt from Client of all API and Client- Supplied Components required for the manufacture of the replacement Product; or 

 

	 	(ii)	 refund [***] percent of the Price paid for the Deficient Product (by credit or offset against other amounts due
to Patheon under the Product Agreement). 

 Except for the indemnity set out in Section 10.3 and any claim for
expenses related to a Recall under Section 6.2(c), the remedies described in this Section 10.2 will be Client’s sole remedy in contract, tort, negligence, equity or otherwise, for Deficient Product. 

The remedy under this Section 10.2, if applicable (including in the case of Recall), will apply only to the extent that the affected
Deficient Product is unsold and returned, destroyed or otherwise disposed of by Client in accordance with this Agreement. 
  

	 	(b)	 API. Except as expressly set out in Appendix 3, under no circumstances whatsoever will Patheon be liable
to Client in contract, tort, negligence, indemnity, breach of statutory duty, or otherwise for any loss or damage to the API. Patheon’s maximum aggregate liability for loss of or damage to the API will not exceed on a per Product basis [***]
percent of revenues (being payments of the Price) received by Patheon for that Product under the applicable Product Agreement during the previous Year (or, in the case of the first Year, the expected revenue for that Product if the agreed Yearly
Forecast Volumes were ordered). 

  
 21 

	 	(c)	 Maximum Liability. In any Year, in addition to the specific remedies under Section 10.2(a) for
Deficient Product, Patheon’s maximum aggregate liability to Client under or in connection with this Agreement or any Product Agreement (however arising, including contract, tort, negligence, indemnity, breach of statutory duty, losses of API,
or otherwise) will not exceed on a per Product basis [***] percent of revenues (being payments of the Price) received by Patheon for that Product under the applicable Product Agreement during the previous Year (or, in the case of the first Year, the
expected revenue for that Product if the agreed Yearly Forecast Volumes were ordered). 

  

	 	(d)	 Death, Personal Injury and Fraudulent Misrepresentation. Nothing contained in this Agreement will act to
exclude or limit either party’s liability for personal injury or death caused by the negligence of either party or fraudulent misrepresentation. 

  

	10.3	 Patheon Indemnity. 

 

	 	(a)	 Patheon agrees to defend, indemnify and hold harmless Client, its officers and employees, against all losses,
damages, costs, claims, demands, subpoenas, judgments and liability to, from and in favour of third parties (other than Affiliates) for i) any claim of infringement of any Third Party Rights by Patheon Intellectual Property, ii) for any claim of a
breach of any warranty or representation by Patheon or iii) for any claim of personal injury or property damage to the extent that the injury or damage is the result of a failure by Patheon to perform the Manufacturing Services in accordance with
the Processing Instructions, cGMPs, and Applicable Laws except to the extent that the losses, damages, costs, claims, demands, subpoenas, judgments, and liability are due to the negligence or wrongful acts of Client, its officers, employees, or
Affiliates. 

  

	 	(b)	 If a claim occurs, Client will: (i) promptly notify Patheon of the claim; (ii) use commercially
reasonable efforts to mitigate the effects of the claim; (iii) reasonably cooperate with Patheon in the defense of the claim; and (iv) permit Patheon to control the defense and settlement of the claim, all at Patheon’s cost and
expense; provided that Client consents in writing to any settlement. 

  

	10.4	 Client Indemnity. 

 

	 	(a)	 Client agrees to defend and indemnify and hold harmless Patheon, its officers and employees, against all
losses, damages, costs, claims, demands, subpoenas, judgments and liability to, from and in favour of third parties (other than Affiliates) for i) any claim of infringement of any Third Party Rights in or the Products or that relates to the
manufacture of the Product by a proprietary process disclosed by Client or to Patheon’s use of Client’s Intellectual Property to perform the Manufacturing Services, or any portion of them, ii) any claim of a breach of any of warranty or
representation by Client, or iii) any claim of personal injury or property damage to the extent that the injury or damage arises other than from a breach of the relevant Product Agreement by Patheon, including, without limitation, any representation
or warranty contained in this Agreement, except to the extent that the losses, damages, costs, claims, demands, subpoenas, judgments, and liability are due to the negligence or wrongful acts of Patheon, its officers, employees, or Affiliates.

 If a claim occurs, Patheon will: (i) promptly notify Client of the claim; (ii) use commercially reasonable
efforts to mitigate the effects of the claim; (iii) reasonably cooperate with Client in the defense of the claim; and (iv) permit Client to control the defense and settlement of the claim, all at Client’s cost and expense; provided
that Patheon consents in writing to any settlement.. 

  
 22 

	10.5	 Reasonable Allocation of Risk. 

This Agreement (including, without limitation, this Section 10) is reasonable and creates a reasonable allocation of risk for the relative
profits the parties each expect to derive from the Product assuming the Product is correctly manufactured, stored and delivered by Patheon in accordance with the terms and conditions of this Agreement. Patheon assumes only a limited degree of risk
arising from the manufacture, distribution, and use of the Product because Client has developed and holds the marketing approval for the Product, Client requires Patheon to manufacture and label the Product strictly in accordance with the Processing
Instructions, and Client, not Patheon, is best positioned to inform and advise potential users about the circumstances and manner of use of the Product. 
  

	10.6	 Validation Batches. 

Where Product is manufactured by Patheon (or any of its Affiliates) under a separate pharmaceutical development or technology transfer
agreement (the “Development Agreement”) and then released by Patheon for commercial sale or distribution by Client, the performance of the applicable pharmaceutical development or technology transfer services
including the manufacture of the Product will be governed by the terms of the Development Agreement and will not be subject to the terms and conditions of this Agreement. The terms of this Agreement and the applicable Product Agreement will apply to
any Product after release by Patheon. 
  

	11.	 Confidentiality 

 

	11.1	 Confidential Information. 

“Confidential Information” means any and all information disclosed by the Disclosing Party to the Recipient (whether
disclosed in oral, written, electronic or visual form) that is non-public, confidential or proprietary including, without limitation, information relating to the Disclosing Party’s patent and trademark
applications, process designs, process models, drawings, plans, designs, data, databases and extracts therefrom, formulae, methods, know-how and other intellectual property, its clients and its clients’
confidential information, finances, marketing, products and processes and all price quotations, manufacturing or professional services proposals, information relating to composition, proprietary technology, and all other information relating to
manufacturing capabilities and operations. In addition, all analyses, compilations, studies, reports or other documents prepared by any party’s Representatives containing Confidential Information will be considered Confidential Information.
Samples or materials provided under this Agreement as well as any and all information derived from the approved analysis of the samples or materials will also constitute Confidential Information. A party’s rights and obligations under this
Section 11 will apply to any Confidential Information that is disclosed by or received by that party’s Representatives. For the purposes of this Section 11, a party receiving Confidential Information under this Agreement (including
through its Representatives) is a “Recipient”, and a party disclosing Confidential Information under this Agreement (including through its Representatives) is the “Disclosing Party”. The existence, parties
to, and terms of this Agreement or of any Product Agreement will be considered Confidential Information. 
  

	11.2	 Use of Confidential Information. 

The Recipient will use the Confidential Information solely for the purpose of meeting its obligations under this Agreement or a related
agreement. The Recipient will now, and in the future, keep the Confidential Information strictly confidential and will not disclose the Confidential Information in any manner whatsoever, in whole or in part, other than to those of its
Representatives who: (i) have a need to know the Confidential Information for the purpose of this Agreement; (ii) have been advised of the 

  
 23 

 
confidential nature of the Confidential Information and (iii) have obligations of confidentiality and non-use to the Recipient no less restrictive
than those of this Agreement. Recipient will protect the Confidential Information disclosed to it by using reasonable precautions to prevent the unauthorized disclosure, dissemination or use of the Confidential Information, which precautions will
not be less than those exercised by Recipient for its own confidential or proprietary Confidential Information of a similar nature. 
  

	11.3	 Exclusions. 

The obligations of confidentiality in this Section 11 will not apply to the extent that Confidential Information: 

 

	 	(a)	 is or becomes publicly known through no breach of this Agreement or fault of the Recipient or its
Representatives; 

  

	 	(b)	 is in the Recipient’s possession at the time of disclosure by the Disclosing Party, as evidenced by the
Recipient’s competent written records, other than as a result of the Recipient’s breach of any legal obligation; 

  

	 	(c)	 is or becomes known to the Recipient on a non-confidential basis
through disclosure by sources, other than the Disclosing Party, having the legal right to disclose the Confidential Information, if the other source is not known by the Recipient to be bound by any obligations (contractual, legal, fiduciary, or
otherwise) of confidentiality to the Disclosing Party for the Confidential Information; 

  

	 	(d)	 is independently developed by employees, advisors or consultants of the Recipient not involved with Client and
without use of or reference to the Disclosing Party’s Confidential Information as evidenced by Recipient’s competent written records; or 

  

	 	(e)	 is expressly authorized for release by the written authorization of the Disclosing Party.

 Any combination of information which comprises part of the Confidential Information is not exempt from the obligations
of confidentiality merely because individual parts of that Confidential Information are covered by exceptions in this Section 11.3, unless the combination itself is covered by any of those exceptions. 

 

	11.4	 Photographs and Recordings. 

Neither party will take any photographs or videos of the other party’s facilities, equipment or processes, nor use any other audio or
visual recording equipment (such as camera phones) while at the other party’s facilities, without that party’s express written consent. 
  

	11.5	 Permitted Disclosure. 

Notwithstanding any other provision of this Agreement, the Recipient may disclose Confidential Information of the Disclosing Party to the
extent required, as advised by counsel, in response to a valid order of a court or other governmental body or as required by law, regulation or stock exchange rule. But the Recipient will advise the Disclosing Party in advance of the disclosure and
limit the required disclosure to the extent practicable and permissible by the order, law, regulation or stock exchange rule and any other applicable law, will reasonably cooperate with the Disclosing Party, if required, in seeking an appropriate
protective order or other remedy, and will otherwise continue to perform its obligations of confidentiality set out in this Agreement. If any public disclosure is required by law, the parties will consult concerning

  
 24 

 
the form of announcement prior to the public disclosure being made. Further, the Client shall be entitled to disclose Confidential Information to any Regulatory Authority, investors and potential
investors, landlords, financing parties; including investment bankers, securities regulators, current officers, directors, stockholders, potential collaborators; provided, however, that if any such third party: (i) refuses to sign a
Confidentiality Agreement with terms substantially similar to the terms in this Article 11 and (ii) is requesting Patheon Confidential Information , then Client agrees that it will not disclose such Confidential Information to the third party
without first notifying Patheon and the Parties mutually agreeing to the process for the disclosure of such information. 
  

	11.6	 Marking. 

The Disclosing Party will use reasonable efforts to summarize in writing the content of any oral disclosure or other non-tangible disclosure of Confidential Information within [***] of the disclosure, but failure to provide this summary will not affect the nature of the Confidential Information disclosed if the Confidential
Information was: (i) identified as confidential or proprietary when disclosed orally or in any other non-tangible form and (ii) given the nature of the information, should in the normal course, be
considered and treated as Confidential Information. 
  

	11.7	 Return of Confidential Information. 

Upon the written request of the Disclosing Party, the Recipient will promptly return the Confidential Information to the Disclosing Party or,
if the Disclosing Party directs, destroy all Confidential Information disclosed in or reduced to tangible form including any copies, summaries, compilations, analyses or other notes derived from the Confidential Information except for one
(1) copy which may be maintained by the Recipient for its records for archival purposes and to ensure compliance with the terms and conditions of this Agreement. The retained copy will be retained by general counsel, or designee, in a secure
environment and will, at all times, remain subject to all confidentiality provisions contained in this Agreement. 
  

	11.8	 Remedies. 

The parties acknowledge that monetary damages may not be sufficient to remedy a breach by either party of this Section 11 and agree that
the non-breaching party will be entitled to seek specific performance, injunctive or other equitable relief to prevent breaches of this Section 11 and to specifically enforce Section 11 in addition
to any other remedies available at law or in equity. These remedies will not be the exclusive remedies for breach of this Section 11 but will be in addition to any and all other remedies available at law or in equity. 

 

	12.	 Intellectual Property 

 

	12.1	 Inventions. 

  

	 	(a)	 For the term of this Agreement as defined in Section 8.1, Client grants to Patheon a non-exclusive, fully paid-up, royalty-free, non-transferable and non-sublicensable (except to
the extent required for any agreed upon subcontracted services) license of Client’s Intellectual Property which Patheon must use in order to perform the Manufacturing Services. 

 

	 	(b)	 All Client Intellectual Property will be and remain the exclusive property of Client. 

  
 25 

	 	(c)	 All Patheon Intellectual Property will be the exclusive property of Patheon. Unless Patheon identifies in
advance any specific Patheon Intellectual Property that will be subject to a separate licensing agreement between the parties and Client consents in advance to use of such Intellectual Property, Patheon hereby grants to Client a non-exclusive, perpetual, fully-paid-up, royalty-free, transferable license with the right to grant sublicenses through all tiers of the Patheon Intellectual Property used by
Patheon in the manufacture of the Product for use in relation to manufacturing that Product and as needed for the commercialization and sale of the Product. 

  

	 	(d)	 Each party will be solely responsible for the costs of filing, prosecution, and maintenance of patents and
patent applications on its own Inventions. 

  

	 	(e)	 Either party will give the other party written notice, as promptly as practicable, of all Inventions which can
reasonably be considered to be improvements or other modifications of the Product, processes or technology owned or otherwise controlled by the party. 

  

	12.2	 Intellectual Property. 

Neither party has, nor will it acquire, any interest in any of the other party’s Intellectual Property unless otherwise expressly agreed
to in writing. Neither party will use any Intellectual Property of the other party, except as specifically authorized by the other party or as required or permitted for the performance of its obligations under this Agreement. 

 

	13.	 Miscellaneous 

 

	13.1	 Insurance. 

Each party will maintain commercial general liability insurance, including blanket contractual liability insurance covering the obligations of
that party under this Agreement through the term of this Agreement and for a period of [***] after that. This insurance will have policy limits of not less than: (i) USD [***] for each occurrence for personal injury or property damage
liability; and (ii) USD [***] in the aggregate per annum for product and completed operations liability. Any combination of Primary and Excess Umbrella Liability policies may be utilized to maintain the required limits. If requested each party
will give the other a certificate of insurance evidencing the above and showing the name of the issuing company, the policy number, the effective date, the expiration date, and the limits of liability. The insurance certificate will further provide
for a minimum of [***] written notice to the insured of a cancellation of, or material change in, the insurance. If a party is unable to maintain the insurance policies required under this Agreement through no fault of its own, then the party will
without delay notify the other party in writing and the parties will in good faith negotiate appropriate amendments to the insurance provision of this Agreement in order to provide adequate assurances. 

 

	13.2	 Independent Contractors. 

The parties are independent contractors and this Agreement, and any Product Agreement does not create between the parties any other
relationship such as, by way of example only, that of employer and employee, principal and agent, joint-venturers, co-partners, or any similar relationship, the existence of which is expressly denied by the
parties. 

  
 26 

	13.3	 No Waiver. 

Neither party’s failure to require the other party to comply with any provision of this Agreement or any Product Agreement will be
considered a waiver of the provision or any other provision of this Agreement or any Product Agreement, with the exception of Sections 6.1 and 8.2 of this Agreement. 
  

	13.4	 Assignment. 

  

	 	(a)	 Patheon may not assign this Agreement or any Product Agreement or any of its associated rights or obligations
without the written consent of Client, this consent not to be unreasonably withheld. 

  

	 	(b)	 Subject to Section 8.2(e), Client may assign this Agreement or any Product Agreement or any of its
associated rights or obligations without approval from Patheon. However, Client agrees that it will give Patheon prior written notice of any assignment, and any assignee will covenant in writing with Patheon to be bound by the terms of this
Agreement or the Product Agreement, and Client will remain liable under this Agreement Any Partial Assignment will be subject to Patheon’s cost review of the assigned Product and Patheon may terminate this Agreement or any Product Agreement or
any assigned part of them, on [***] prior written notice to Client and the assignee if good faith discussions do not lead to agreement on amended Manufacturing Service fees within a reasonable time. Client will reimburse Patheon for any reasonable
costs incurred by Patheon in connection with the Partial Assignment including any expenses incurred by Patheon for any due diligence audits in connection with the Partial Assignment. 

 

	 	(c)	 Despite the preceding provisions of this Section 13.4, either party may assign this Agreement or any
Product Agreement, without any consent of approval of the other Party, but upon written notice to the other Party, to any of its Affiliates or to a successor to or purchaser of all or substantially all of its business or equity securities or
pursuant to a merger, consolidation, acquisition or other business combination, provided the assignee executes an agreement with the non-assigning party whereby the assignee agrees to be bound by the
obligations of this Agreement. 

  

	13.5	 Force Majeure. 

Neither party will be liable for the failure to perform its obligations under this Agreement or any Product Agreement if the failure is caused
by an event beyond that party’s reasonable control, consisting of: strikes or other labor disturbances, lockouts, riots, quarantines, communicable disease outbreaks, wars, acts of terrorism, cyber-attacks, fires, floods, storms, interruption of
or delay in transportation, lack of or inability to obtain fuel, power or components, or compliance with any order, regulation, or enforcement decision of any government entity (a
“Force Majeure Event”). A party claiming a right to excused performance under this Section 13.5 will immediately notify the other party in writing of the extent of its inability to perform,
which notice will specify the event beyond its reasonable control that prevents the performance and only so long as the Force Majeure event exists. Neither party will be entitled to rely on a Force Majeure Event to relieve it from an obligation to
pay money (including any interest for delayed payment of an undisputed amount) which would otherwise be due and payable under this Agreement or any Product Agreement. If due to Force Majeure Event, Patheon is unable to supply Client with the Product
for a period exceeding [***] then Client shall have the right to terminate this Agreement without further cost and with immediate effect and upon written notice to Patheon. At the end of the first [***] during the persistence of the Force Majeure
Event Patheon shall reasonably determine whether it will be able to resume supplying Product at the end of such [***] period and notify Client in writing of such assessment. If Patheon has concluded that it will be unable to resume supplying Product
at the end of such period Client shall have the right to terminate this Agreement without cost. Patheon will provide all reasonable assistance during the technology transfer for the Product upon termination due to force majeure per Section 8.4.

  
 27 

	13.6	 Additional Product and Services. 

Additional Product may be added to, or existing Product deleted from, any Product Agreement by amendment to the Product Agreement including its
Schedules as applicable. If Client requests services other than those expressly set out in this Agreement or in any Product Agreement (such as qualification of a new packaging configuration or shipping studies, or validation of alternative batch
sizes), or any cost items that are specifically excluded from the Price, Patheon will provide a written quote of the fee for the additional services and Client will advise Patheon whether it wishes to have the additional services performed by
Patheon. The scope of work and fees will be agreed in writing by the parties. 
  

	13.7	 Notices. 

All notices under this Agreement, a Product Agreement, Quarterly Agreement and other agreement shall be in writing. Further, unless otherwise
agreed in a Product Agreement, any notice, approval, instruction or other written communication required or permitted under this Agreement will be sufficient if made or given to the other party by personal delivery or confirmed receipt email or by
sending the same by first class mail, postage prepaid to the respective addresses or email addresses set out below: 
 If to Client: 

Amylyx Pharmaceuticals, Inc. 
 43
Thorndike Street 
 Cambridge, MA 02141 

Attention: [***] 
 Email address:
[***] 
 With a copy, which shall not constitute notice, to: 

Rubin and Rudman LLP 
 53 State
Street, 15th Floor 
 Boston, MA 02109 

Attn: [***] 
 Email address: [***]

 If to Patheon: 
 PATHEON INC.

 111 Consumers Road 
 Whitby,
ON L1N 5Z5 
 Attention: [***] 

Email address: 
 With a copy to:

 Attention: [***] (at the same address) 

or to any other addresses or email addresses given to the other party in accordance with the terms of this Section 13.7. Notices or
written communications made or given by personal delivery, or email will be considered to have been sufficiently made or given when sent (receipt acknowledged), or if mailed, five days after being deposited in the United States, Canada, or European
Union mail, postage prepaid or upon receipt (supported by reasonable written evidence), whichever is sooner. 

  
 28 

	13.8	 Severability. 

If any provision of this Agreement or any Product Agreement is determined by a court of competent jurisdiction to be invalid, illegal, or
unenforceable in any respect, that determination will not impair or affect the validity, legality, or enforceability of the remaining provisions, because each provision is separate, severable, and distinct. 

 

	13.9	 Entire Agreement and Amendment. 

This Agreement, together with its Appendices, the applicable Product Agreement, Capital Equipment Agreement (if any), and the Quality
Agreement, constitutes the full, complete, final and integrated agreement between the parties relating to the subject matter of the Agreement and supersedes all previous written or oral negotiations, commitments, representations, agreements,
transactions, or understandings concerning the subject matter of this Agreement. The basis of the parties’ agreement is set out expressly and they have not been induced by or relied on any statement or representation that is not set out in this
Agreement. Any modification, amendment, or supplement to this Agreement or any Product Agreement must be in writing and signed by authorized representatives of both parties. In case of conflict, the prevailing order of documents will be this
Agreement, the Product Agreement, and the Quality Agreement (except that the Quality Agreement will prevail in relation to quality matters). 
  

	13.10	 Other Terms. 

No terms, provisions or conditions of any purchase order or other business form or written authorization used by the parties will have any
effect on the rights, duties, or obligations of the parties under or otherwise modify this Agreement or any Product Agreement, regardless of any failure of a party to object to the terms, provisions, or conditions unless the document specifically
refers to this Agreement or the applicable Product Agreement and is signed by both parties. 
  

	13.11	 No Third Party Benefit or Right. 

Nothing in this Agreement or any Product Agreement will confer or be construed as conferring on any third party any benefit or the right to
enforce any express or implied term of this Agreement or any Product Agreement (except that Patheon Affiliates acting as subcontractors under this Agreement may enforce Sections 10.1 and 10.2). The rights of the parties to terminate, rescind or
agree any variation, waiver or settlement under this Agreement are not subject to the consent of any other person. 
  

	13.12	 Execution in Counterparts. 

This Agreement and any Product Agreement may be executed in two or more counterparts, by original or electronic (including
“pdf”) signature, each of which will be considered an original, but all of which together will constitute one and the same instrument. 
  

	13.13	 Use of Name. 

Neither party may use the other party’s name, trademarks or logo or any variations of them, alone or with any other word or words, without
the prior written consent of the other party. Despite this, Client agrees that Patheon may include Client’s name and logo in customer lists or related marketing and promotional material for the purpose of identifying users of Patheon’s
Manufacturing Services. 

  
 29 

	13.14	 Taxes. 

  

	 	(a)	 VAT. 

Any payment due to Patheon under this Agreement in consideration for the provision of Manufacturing Services to Client by Patheon is exclusive
of value added taxes (“VAT”), turnover taxes, sales taxes or similar taxes, including any related interest and penalties (together referred to as “Transaction Tax”). If any Transaction Tax is payable on a
Manufacturing Service supplied by Patheon to Client under this Agreement, this Transaction Tax will be added to the invoice amount and will be for the account of (and reimbursable to Patheon by) Client. 

If any Transaction Tax on the supplies by Patheon is payable by Client under a reverse charge or withholding procedure (i.e., shifting of
liability, accounting or payment requirement to recipient of supplies), Client will ensure that Patheon will not effectively be held liable for this Transaction Tax by the relevant taxing authorities or other parties. 

Where applicable, Patheon will use its reasonable commercial efforts to ensure that its invoices to Client are issued in a way to meet the
requirements for deduction of input VAT by Client, if Client is permitted by law to do so. 
 Each party will provide the other with
reasonable assistance to enable the recovery, as permitted by Applicable Laws, of Transaction Tax resulting from payments made under this Agreement, this recovery to be for the benefit of the party bearing the Transaction Tax. 

If Patheon is acting as Client’s buying agent, Patheon will always charge to Client the Transaction Tax in the relevant territory in
addition to the amount paid by Patheon to supplier. 
 For the avoidance of doubt, reference to the Manufacturing Services in this Section
also includes any element (or the entirety) of the Manufacturing Services characterized as a supply of goods by Patheon, its subcontractors or any tax authority for Transaction Tax purposes. 

 

	 	(b)	 Duties. 

Client will bear the cost of all duties, levies, tariffs and similar charges (and any related interest and penalties) (together
“Duties”) however designated, arising from the performance of the Manufacturing Services by Patheon, including (without limitation) those imposed as a result of the shipping of materials (including drug substance, materials,
components and finished Product) to, from or between Patheon sites. If these Duties are incurred by Patheon, then Patheon will be entitled to invoice Client for these Duties at the time that they are incurred. 

 

	 	(c)	 Withholding Tax. 

Where any sum due to be paid to Patheon hereunder is subject to any withholding or similar tax, Client will pay the withholding or similar tax
to the appropriate Government Authority without deduction from or offset of the amount then due to Patheon. The Parties agree to cooperate with one another and use reasonable efforts to reduce or eliminate or enable the recovery of any tax
withholding or similar obligations in respect of royalties, milestone payments, and other payments made by Client to Patheon under this Agreement. 

Patheon will provide Client any tax forms that may be reasonably necessary in order for Client not to withhold tax or to withhold tax at a
reduced rate under an applicable bilateral income tax treaty. 

  
 30 

 Each Party will provide the other with reasonable assistance to enable the recovery, as
permitted by Applicable Laws, of withholding taxes, or similar obligations resulting from payments made under this Agreement, this recovery to be for the benefit of the Party bearing the withholding tax. 

 

	 	(d)	 No Offset. Any Transaction Tax, Duty, Withholding Tax or other tax that Client pays, or is required to
pay, but which Client believes should properly be paid by Patheon under this Agreement may not be offset against sums due by Client to Patheon whether due under this Agreement or otherwise. 

 

	13.15	 Governing Law and Jurisdiction. 

This Agreement and any Product Agreement, and any dispute or claim (including non-contractual disputes
or claims) arising out of or in connection with them or their subject matter or formation are governed by the laws of the State of Delaware without regard to any
conflicts-of-law principle that directs the application to another jurisdiction’s law. Both parties hereby submit to the exclusive jurisdiction of the courts
located in the State of Delaware. The parties further expressly agree that the UN Convention on Contracts for the International Sale of Goods will not apply to this Agreement. 
  

	13.16	 Dispute Resolution. 

All disputes that arise under or in connection with this Agreement will be resolved in accordance with Appendix 2. 

SIGNATURE PAGE TO FOLLOW 

  
 31 

 This Agreement is signed by the authorized representatives of the parties on the dates shown below and will
take effect from the Effective Date. 
  

					
	PANTHEON INC.	 	    	  	AMYLYX PHARMACEUTICALS, INC.
			
	 By: /s/ Don
Liscombe                                        
            
 Name: Don Liscombe

Title: General Manager, Commercial Operations
 Date:
November 19, 2019
	 		  	 By: /s/ Justin
Klee                                         
           
 Name: Justin Klee

Title: President
 Date: November 12, 2019

  
 32 

 APPENDIX 1—Form of Product Agreement 

Product Agreement for [INSERT PRODUCT NAME] 

This Product Agreement (this “Product Agreement”) is issued under the Master Manufacturing Services Agreement dated
October 1, 2019 between PATHEON INC. and AMYLYX PHARMACEUTICALS, INC., (the “Master Agreement”), and is entered into on [INSERT DATE] (the “Effective Date”) between [PATHEON ENTITY], a corporation existing
under the laws of [ ], having a principal place of business at [PATHEON ENTITY ADDRESS] (“Patheon”) and Amylyx Pharmaceuticals, Inc., a Delaware corporation having a principal place of business at 43 Thorndike Street, Cambridge, MA
02141 (“Client”). For the purpose of this Product Agreement, references in the Master Agreement to “Patheon” and “Client” mean the entities defined respectively as Patheon and Client in this Product Agreement.

 The terms and conditions of the Master Agreement are incorporated into this Product Agreement except to the extent this Product Agreement
expressly modifies specific provisions in the Master Agreement. All capitalized terms that are used but not defined in this Product Agreement will have the respective meanings given to them in the Master Agreement. 

 

	 	1.	 Initial Product Term: will be from the Effective Date until December 31, 20[ ]

  

	 	2.	 Manufacturing Site: The Manufacturing Services will be performed at the following Manufacturing Site: [
] 

  

	 	3.	 Minimum Market Requirement: (if different from the Master Agreement, capture Launch Period and period
following the Launch Period) 

  

	 	4.	 Notices: (if different from Section 13.7 of the Master Agreement): [insert contact details]

  

	 	5.	 API Name: [insert API name] 

 

	 	6.	 API Credit Value: Client’s actual cost for API not to exceed [ ] per kilogram. API value to be
provided by Client and supported by such reasonable evidence as Patheon requests. 

  

	 	7.	 Local Currency: [insert currency] 

 

	 	8.	 Billing Currency: [insert currency] 

 

	 	9.	 Initial Exchange Rate: [1.00 Local Currency] to [1.00 Billing Currency] 

 

	 	10.	 Inflation Index: [if different from the Master Agreement] 

 

	 	11.	 Governing Law: [if different from the Master Agreement]] 

 

	 	12.	 Other Modifications to the Master Agreement (if any): [insert here; for currencies not in EURO or USD,
insert the following language: The parties agree that for purposes of this Product Agreement, all references in the Master Agreement to EURO/USD are hereby converted to [CAD] at the exchange rate of 1 EURO/USD to x [CAD].] 

  
 1 

 Schedule A - Commercial Supply Pricing Proposal: Description of the Manufacturing
Services and related terms of this Product Agreement, which may include: Product Features and Assumptions, Key Assumptions to be Finalized, Annual Volume Forecasts, Pricing Tables, Costs Included in Price, Costs Not Included in Price, Equipment
Requirements (if applicable), Manufacturing Parameters, Packaging Parameters, Testing Conditions, Supply Chain. 
 In case of conflict between Schedule A
and the other parts of this Product Agreement, those other parts will prevail. 
 This Agreement is signed by the authorized representatives
of the parties on the dates shown below and will take effect from the Effective Date. 
  

					
	[PANTHEON ENTITY]	 		  	AMYLYX PHARMACEUTICALS, INC.
			
	
By:                         
                                         
                            

Name:
                                         
                                         
      
 Title:
                                         
                                         
        
 Date:
                                         
                                         
        
	 	 
     

 
	  	
By:                         
                                         
                            

Name:                         
                                         
                       
 Title:
                                         
                                         
        
 Date:
                                         
                                         
        

  
 2 

 Schedule A - Commercial Supply Pricing Proposal 

[Insert Commercial Supply Pricing Proposal] 

[End of Product Agreement] 

  
 3 

 APPENDIX 2 - Dispute Resolution 

Negotiation 
 If any dispute arises out of this Agreement
or any Product Agreement, the parties will first try to resolve it amicably. Any party may send a notice of a dispute to the other, and each party will appoint, within [***] from receipt of the notice, an appropriate single representative having
full power and authority to resolve the dispute. The representatives will meet as necessary in order to resolve the dispute. If the representatives fail to resolve the matter within [***] from their appointment, or if a party fails to appoint a
representative as required above: for Technical Disputes, the expert determination procedure may be started by either party; and for all other disputes, each party will refer the dispute immediately to the Chief Operating Officer or equivalent (or
another senior manager as he/she may designate) (“Senior Officers”) who will meet and discuss as necessary to try to resolve the dispute amicably. 

Mediation 
 If the Senior Officers fail to resolve the
dispute, the parties will attempt in good faith to settle the dispute promptly by confidential mediation under the then current CPR Mediation Procedure, before resorting to litigation. If one party fails to participate in settlement negotiations as
provided in this Appendix 2, the other party may initiate mediation prior to the expiration of the applicable negotiation periods. The mediator will be chosen with the assistance of CPR (and CPR’s choice will be accepted by the parties in the
absence of conflict or bias), unless the parties agree on a specific mediator in writing within [***] of the referral to mediation. The mediation will take place in Boston, Massachusetts and the language of the mediation will be English. Unless
otherwise agreed, the parties will select a mediator from the CPR Panels of Distinguished Neutrals. 
 Except where proceedings are required for the purpose
of an interim injunction or other interim equitable relief or to preserve a party’s legal position following the outcome of negotiation or mediation, neither party may commence any court proceedings in relation to a dispute until the required
mediation has ended without resolving that dispute or a party fails to participate in that mediation. Where a party decides not to take part in mediation in contravention of this Appendix 2, it will send written notice of that decision to the
other party. 
 Technical Disputes 
 If a dispute arises
between the parties that is exclusively related to technical aspects of the manufacturing, packaging, labelling, quality control testing, handling, storage, or other activities under this Agreement, including conformance of Product to applicable
specifications (a “Technical Dispute”), the parties will use all reasonable efforts to resolve the dispute by amicable negotiations as provided above. If the parties are unable to resolve a Technical Dispute by
negotiation, the Technical Dispute will, at the written request of either party, be referred for determination to an expert in the following manner: 
  

	(a)	 Appointment of Expert. Within [***] after the written request, the parties will appoint a single agreed
expert with experience and expertise in the subject matter of the dispute. If the parties fail to agree the appointment within that period, then either party may request that a neutral from the International Institute of Conflict Prevention and
Resolution appoints a suitable expert (and both parties will accept that appointment in the absence of evident conflict or bias). As a condition of the expert’s appointment, the parties will ensure that the expert agrees to disclose any actual
or potential conflicts of interest promptly as they arise. The parties do not intend that the expert acts as an arbitrator. 

  
 1 

	(b)	 Procedure. The parties will require the expert to provide an opinion on each referred issue (with
reasonably detailed reasoning) within [***] (or as agreed by the parties with the expert). Each party will give to the expert all the evidence and information within their respective possession or control as the expert may reasonably request, which
they will disclose promptly and in any event within [***] of a written request from the expert to do so. At all times the parties will co-operate in good faith and seek to narrow and limit the issues to be
determined. 

  

	(c)	 Final and Binding. The determination of the expert will, except for fraud or manifest error or where an
unapproved conflict of interest is discovered, be final and binding upon the parties with respect to the referred Technical Dispute. 

  

	(d)	 Costs. Each party will bear its own costs for any matter referred to an expert under this Appendix 2
and, in the absence of express agreement to the contrary, the costs and expenses of the expert will be shared equally by the parties. 

  
 2 

 APPENDIX 3 - API Yield Calculation 

Actual Annual Yield 
 Reconciliation: For each
Year, Patheon will prepare an annual reconciliation of API including the calculation of the Actual Annual Yield as set forth below. 

“Actual Annual Yield” means the percentage of the Quantity Dispensed that was converted to Products for the Product at the
Manufacturing Site in that Year and is calculated as follows: 
  
 

 
 “Quantity Dispensed” means the API received and dispensed in commercial
manufacturing of Product, calculated as follows: 
 The total quantity of API that complies with the specifications and is received at the
Manufacturing Site during the Year added to the inventory of API that complies with the specifications held at the start of the Year, minus the inventory of API that complies with the specifications held at the end of the Year. 

The Quantity Dispensed includes API lost in the warehouse prior to and during dispensing but excludes (i) API retained by Patheon as
samples; (ii) API contained in Product retained as samples; (iii) API used in testing (if applicable); (iv) API contained in Product that is rejected for specific market related requirements such as visual inspection of the Product that is
not part of normal processing and (v) API received or dispensed in technical transfer activities or development activities, including without limitation, any regulatory, stability, validation or test batches manufactured during the applicable
period. 
 “Quantity Converted” means the total amount of API contained in the Product manufactured with the Quantity
Dispensed (including any additional Product supplied as a replacement remedy) and released for delivery, but not rejected as Deficient Product in accordance with Section 6.1. The quantity of API contained in Deficient Product will be included
in the Quantity Dispensed but not in the Quantity Converted. 
 Target Yield and Credit Calculation 

After Patheon has produced a minimum of ten successful commercial production batches of Product and has produced commercial production batches for at least six
months at the Manufacturing Site, the parties will agree on the target yield for the Product at the Manufacturing Site (as a percentage of the Quantity Dispensed to be converted to Product, this percentage a “Target Yield”). After
the six month period, and then before the start of each subsequent Year, the parties will enter into good faith discussions to agree on a Target Yield for that Year which reasonably reflects the actual manufacturing experience of Patheon to date.
Once the Target Yield is agreed, the following applies: 
 Shortfall Credit Calculation. If the Actual Annual Yield falls greater than [***] below
the respective Target Yield in a Year, then the shortfall credit for the Year (the “Shortfall”) will be calculated as follows: 
  

 

  
 1 

 Surplus Credit Calculation. If the Actual Annual Yield is greater than the respective Target Yield in
a Year, then the surplus credit for that Year (the “Surplus”) will be determined based on the following calculation: 
  

 
 Shortfall Credit. If there is a Shortfall for a Product in a Year, then Patheon will credit Client’s account
for the amount of the Shortfall not later than [***] after the end of each Year. 
 Surplus Credit. If there is a Surplus for a Product in a Year,
then Patheon will be entitled to apply the amount of the Surplus as a credit against any Shortfall for that Product which may occur in the next Year. If there is no Shortfall in the next Year the Surplus credit will expire. 

Each credit under this paragraph will be summarized in an annual reconciliation report. Upon expiration or termination of a Product Agreement, any remaining
Shortfall credit amount owing under this paragraph will be paid to Client. 
 Limits on API Liability 

A Shortfall caused by rejected Deficient Product (including in the case of Recall) will only result in a Shortfall Credit to the extent the affected Product is
unsold and returned, destroyed or otherwise disposed of by Client in accordance with the terms of this Agreement. 
 Any payable reimbursement (within the
maximum liability limits) for lost API will be made at the API Credit Value. 

  
 2 

 APPENDIX 4 - Price Adjustments 

Price Adjustment Calculation Due To Inflation 
 Refer to
Section 4.2(a) 
 Definitions: 

“Inflation Index” means the overall harmonised Index of Consumer Prices (HICP) published by the European Central Bank
(www.ecb.europa.eu/stats/prices/hicp/html/index.en.html) for Manufacturing Sites in Europe, and the Producer Price Index pcu32541235412 for Pharmaceutical Preparation Manufacturing (PPI) published by the United States Department of Labor,
Bureau of Labor Statistics (hyperlink) for Manufacturing Sites in North America. 
 “Inflation Percentage” means the average
of the monthly annual percentage changes in the Inflation Index from September of the preceding Year to August of the then current Year. For example, at the end of 2019 the new Inflation Percentage would be calculated as follows (figures are for
illustration only): 
  

									
	 From: Month - Year
	  	To: Month - Year	 	  	Annual Percentage Change	 
	 September - 2017
	  	 	September - 2018	 	  	 	0.7	% 
	 October - 2017
	  	 	October - 2018	 	  	 	1.1	% 
	 November - 2017
	  	 	November - 2018	 	  	 	1.0	% 
	 December - 2017
	  	 	December - 2018	 	  	 	0.8	% 
	 January - 2018
	  	 	January - 2019	 	  	 	0.8	% 
	 February - 2018
	  	 	February - 2019	 	  	 	1.1	% 
	 March - 2018
	  	 	March - 2019	 	  	 	1.1	% 
	 April - 2018
	  	 	April - 2019	 	  	 	1.5	% 
	 May - 2018
	  	 	May - 2019	 	  	 	1.7	% 
	 June - 2018
	  	 	June - 2019	 	  	 	1.4	% 
	 July - 2018
	  	 	July - 2019	 	  	 	1.2	% 
	 August - 2018
	  	 	August - 2019	 	  	 	1.1	% 
	 Inflation Percentage
	  
	  	 	1.13	% 

 Calculation: 
  

 
 Price Adjustment Calculation Due To Currency Fluctuation 

Refer to Section 4.2(b) 
 Definitions: 

“Billing Currency” means the currency in which the Manufacturing Services will be invoiced and paid as specified in the
Product Agreement. 
 “Local Currency” means the currency that is used in the country where the Manufacturing Site is
located as specified in the Product Agreement. 

  
 1 

 “Initial Exchange Rate” means the initial exchange rate set out in the
Product Agreement to convert one unit of the Patheon Manufacturing Site Local Currency into the Billing Currency for the first Year of the Product Agreement. 

“Current Year Exchange Rate” means the exchange rate calculated as of the current Year of the Product Agreement (starting from
the second year), and is calculated as the average interbank exchange rate for conversion of one unit of the Patheon Manufacturing Site Local Currency into the Billing Currency during the period (September 1st of the preceding year to August 31st of the current year) as published by OANDA.com under the heading “Average Exchange Rates” at www.oanda.com/currency/average. 

“Preceding Year Exchange Rate” means the exchange rate calculated in the previous Year to the then current Year of the Product
Agreement. 
 Calculation: 
  

 
 For example: 
  

			
	 Billing Currency
	  	USD
	 Local Currency
	  	EURO
	 Current Price (after inflation)
	  	1.50 USD
	 Preceding Year Exchange Rate
	  	1.2 (1 EURO to 1.2 USD)
	 Current Year Exchange Rate
	  	1.1 (1 EURO to 1.1 USD)
	 New Price
	  	

  
 2EX-10.15

 Exhibit 10.15 

Certain identified information has been excluded from this exhibit because it is both not material and 

is the type that the registrant treats as private or confidential. Information that was omitted has been 

noted in this document with a placeholder identified by the mark “[***]”. 

 
  

SUPPLY 
 AGREEMENT

  
  

This Supply Agreement (the “Agreement”) dated as of October 29, 2019 (the “Effective Date”), is made and entered into
by and between: 
 Amylyx Pharmaceuticals, Inc. a corporation incorporated and existing under the laws of the State of Delaware, with registered
offices at 43 Thorndike Street, Cambridge, MA 02141 U.S.A., acting on Its behalf and on behalf of its Affiliates, duly represented by Thomas Holmes, Global Head, Supply Chain; 

(“Buyer”)                   
                                      

AND 
 CU Chemie Uetikon, GmbH, a company incorporated and
existing under the laws of Germany, with registered offices at Raiffeisenstr 4, 77933 Lahr, Germany and registered under number Freiburg HBR 390945 acting on its behalf and on behalf of its Affiliates, duly represented by Frédéric
Desdouits, Managing Director; 
 (“SEQENS CDMO” or
“Supplier”)             
 Both Supplier and Buyer are individually referred to
as a “Party” and collectively, the “Parties”. 
 PREAMBLE: 

WHEREAS, SEQENS CDMO Is the division of the SEQENS group specialized in the manufacture and sale of fine chemicals and active pharmaceutical
ingredients and other specialty molecules for use in the pharmaceutical and chemical industries. For the purpose of this Agreement, an “Affiliate” refers to any legal entity controlled by or under common control with Supplier
(control as defined by the OCDE) that is actively Involved in the performance of this Agreement; 
 WHEREAS, Buyer is developing a product that will
ultimately include the API, as hereinafter defined, to make the Buyer’s finished dose formulation (the “End Product”). The End Product requires for its manufacture the use of the active pharmaceutical ingredient sodium
phenylbutyrate ([***]) produced by Supplier at its Facility (the “API”); 
 WHEREAS, Buyer wishes to secure sourcing of the API
including its registration in the End Product drug master file in view of obtaining its marketing authorisation from the FDA in the United States of America; 

WHEREAS, Supplier has polyvalent manufacturing capacities able to manufacture and supply the API on an industrial and commercial scale. 

 NOW AND THEREFORE, for good and valuable consideration, Including the herein agreements, covenants,
promises, representations and warranties, the receipt and legal sufficiency of which is hereby acknowledged, accepted and agreed to, the Parties hereby agree as follows: 
  

	1.	 Scope 

  

	 	1.1	 During the Term of this Agreement and in accordance with the terms and conditions of this Agreement, Buyer
agrees to purchase from Supplier, on a non-exclusive basis, and Supplier represents, warrants and agrees to timely manufacture, supply and deliver to Buyer, in accordance with this Agreement, all quantities of
API ordered by Buyer for the formulation, distribution and sale of the End Product. The Supplier will purchase sufficient raw materials and schedule the necessary Facilities resources and capacity by allocating a specific time period at the Facility
for the manufacture of the API ordered by the Buyer. Supplier is responsible for all API activities required to be performed under this Agreement and will support all of Buyer’s regulatory filings. 

 

	 	1.2	 The API is supplied on a non-exclusive basis. Supplier shall remain at
all times owner of the End Product’s drug master file and this Agreement shall not prevent Supplier from manufacturing and selling API to third parties. The Supplier shall fully cooperate with the Buyer to provide all required access to the API
DMF and other data that may be required by any relevant regulatory Authority (only the open part DMF will be directly provided to the Buyer) and shall provide worldwide support for the Buyer’s registration and approval of the End Product.

  

	 	1.3	 Buyer is and shall remain the sole owner of the End Product. 

 

	2.	 Condition precedent and subsequent 

 

	 	2.1	 The End Product is currently in an FDA approved clinical trial and the Buyer anticipates receiving marketing
authorizations during [***] (the “MA”) from the relevant regulatory authorities; specifically, the food and drug administration (FDA) for the USA. 

 

	 	2.2	 Prior to reception of the MA, it is understood and agreed that Supplier will manufacture and supply the API in
accordance with special purchase orders to be placed, from time to time, in accordance with the Buyer’s development needs (the “Pre-MA Purchase Order”). 

 

	 	2.3	 Supplier shall make available to Buyer the open part of the DMF. 

 

	3.	 Product and volumes 

 

	 	3.1	 Supplier shall timely manufacture, deliver and supply API in accordance with all of the specifications laid out
Exhibit 1 and this Agreement (the “Specifications”). 

  

	 	3.2	 Supplier shall manufacture the API at its industrial site CU UETIKON located at Raiffeisenstrasse 4 - 77933,
Lahr, Germany (the “Site”). All API shall be manufactured in accordance with cGMP (current Good Manufacturing Practice) as promulgated under the U.S. Federal Food, Drug, and Cosmetic Act at 21 CFR (chapters 210 and 211), as the same
may be amended or re-enacted from time to time. As a condition precedent and prior to Buyer accepting initial delivery of the API, Supplier agrees to provide Buyer with documentation verifying that
Supplier’s plant has been inspected by the U.S. FDA and that it is in good standing with respect to its manufacturing practices as evidenced by an acceptable Establishment Inspection Report issued by the FDA (an “EIR”).
Supplier shall supply promptly deliver to Buyer a copy of each EIR as issued during the Term of this Agreement. 

  
 2 

	 	3.3	 Supplier agrees, during the Term, to obtain and maintain throughout the Term any and all U.S. governmental
approvals, registrations or licenses necessary to manufacture, sell and distribute the API to Buyer; and further agrees to permit the inspection of its plant where the API is being manufactured (the “Facility”) by the Buyer and
authorized representatives of the FDA at all times. 

  

	 	3.4	 Buyer shall order the API in multiples of [***]. All API shall meet the specifications provided by Buyer and
Seller shall provide a Certificate of Analysis (“COA”) with each delivery of API. 

  

	4.	 Capacity constraints and development 

 

	 	4.1	 Supplier represents that it has a current capacity to manufacture [***] per month of API and an aggregate
yearly volume of [***] of API (the “Max Capacity’’). [Consider EX US supply & Japan). The Supplier agrees that it will maintain the Max Capacity during the Term of this Agreement. Notwithstanding anything to the
contrary herein contained, the Supplier represents and warrants that it will have and it will continue to have during the “Launch Period”, as hereinafter defined, the capacity to timely manufacture and deliver to the Buyer all API
ordered by the Buyer. For purposes of this Agreement, the Launch Period is defined to mean the [***] period commencing on the Effective Date and terminating at the end of the [***] following the Effective Date. 

 

	 	4.2	 Supplier may update this Max Capacity from time to time to take account of Buyer’s actual requirements and
those of eventual third party clients. 

  

	 	4.3	 In the event that Buyer’s orders for the API exceed Supplier’s Max Capacity then both Parties shall
discuss commercially viable solutions to increase such Max Capacity. In the event that Buyer orders exceed Supplier’s Max Capacity, whether on a monthly or yearly basis, then Supplier shall only be bound to supply an amount equal to its Max
Capacity as expressed above. For avoidance of doubt, it is understood and agreed that if the Buyer’s requirements exceed the Supplier’s Max Capacity or if Supplier is unable to supply all or any part of the API, then the Buyer, in either
event, shall be entitled without any obligation to the Supplier, to purchase such excess requirements from a third party. 

  

	5.	 Raw materials sourcing 

 

	 	5.1	 Supplier shall be responsible for sourcing, purchasing and supplying all raw material required for the
manufacture of the API. 

  

	 	5.2	 In the event that Supplier discovers any threat to sourcing security that relates to any activity or
obligations of the Buyer, then it shall immediately inform Buyer and Buyer shall reasonably cooperate for the resolution of the issues (such as any regulatory requirement affecting the End Product to qualify a second source). 

  
 3 

	6.	 Forecast 

 

	 	6.1	 Supplier will be manufacturing the API in multipurpose production Facilities at the Site as such it is
understood that the Facilities are used for multiple products and proper planning is required to ensure than the Facilities are adequately available and dedicated to Buyer’s needs. 

 

	 	6.2	 Buyer will therefore provide a [***] rolling forecast updated on a [***] basis. Such forecast shall be non-binding upon the Parties provided, however, that the forecast for the then [***] shall be considered a firm commitment to purchase the quantities of API set forth in such forecast and Supplier represents that
the Facilities will have sufficient capacity and raw materials to supply API, in accordance with this Agreement for at least [***]. The Buyer shall provide an executed purchase order with the applicable quantity forecast and upon other terms and
conditions set forth in the Purchase Order 

  

	 	6.2.1	 Supplier shall not be required to accept any Purchase Orders (as the term is defined hereunder) in excess of
the rolling forecast, but Supplier will use commercially reasonable efforts to accept and complete such Purchase Orders; 

  

	 	6.2.2	 All Purchase Orders shall be placed in accordance with the relevant lead times; 

 

	 	6.2.3	 The forecast may not exceed the defined Max Capacity, unless otherwise agreed to; 

 

	 	6.2.4	 Option to reserve Supplier capacity. In the event that Buyer wishes to reserve a certain capacity of the
production facilities (“Reserved Capacities”) for delivery of API by a specific date it shall have the option, instead of placing a Purchase Order for the API, to place a Capacity Reservation that it shall have the right to cancel,
in part or whole, up to [***] before the scheduled production date. In the event that it does not take all Reserved Capacities, then It shall pay an amount equal to [***] percent ([***]) of the non-used
Reserved Capacities. For the avoidance of doubt, such Reserved Capacities shall be expressed in a number of kilograms of API to be produced in a defined month (subject to Max Capacity). 

 

	7.	 Purchase Orders 

 

	 	7.1	 Buyer shall place orders for API in accordance with this Agreement and Supplier constraints as expressed
hereunder (a “Purchase Order”). Supplier’s form of a Purchase Order is annexed hereto as Exhibit 4 and made a part hereof as if set out verbatim. 

 

	 	7.2	 Such Purchase Order shall be placed with a lead time of [***] prior to the requested delivery date.

  

	 	7.3	 Supplier shall accept or reject any Purchase Order placed in accordance with the Forecast within [***] of
receipt; and if not timely rejected in writing within the aforesaid [***] period ([***]), the Purchase Order shall be deemed automatically accepted without the need for any further action or deed. In the event that Buyer places Purchase Orders in
excess of the Max Capacity or the Forecast then Supplier shall, subject to Section 4, make reasonable commercial efforts to accept such Purchase Orders subject to it adjusting the times and pricing as may be required to meet such additional
demand, 

  

	 	7.4	 Upon acceptation by Supplier, the Purchase Order will become firm and binding between the Parties. In the event
of a conflict between the terms of this Agreement and a Purchase Order then the terms of this Agreement shall control for all purposes unless otherwise agreed to by the Parties In writing in the Purchase Order. Furthermore any standard terms and
conditions sent with or attached to a Purchase Order, its acceptance, a bill of lading, an invoice or any other standard document issued by a Party shall not apply to this Agreement, 

  
 4 

	8.	 Intentionally Deleted. 

 

	9.	 Second Site qualification 

 

	 	9.1	 Buyer shall have the option to request that Supplier qualify a second Site and Facility for production of the
API for business continuity planning subject to the following provisions. 

  

	 	9.2	 Supplier and Buyer shall cooperate fully for the qualification of a second Site and Facility or production line
in order to ensure continuous production of the API and to mitigate the impact from unforeseen circumstances. 

  

	 	9.3	 Buyer and Supplier shall provide all requisite regulatory support to the other party for the registration of
such second Site and Facility in order to ensure that Supplier may produce the API at the second Site and Facility and that Buyer may use such API in its End Product. 

 

	 	9.4	 Upon all regulatory qualification and approval of the second Site and Facility, it is understood and agreed
that Supplier may provide API from either of the Sites and Facility as may be practical for planning purposes. 

  

	 	9.5	 It is understood that for the purpose of the second Site and Facility qualification, Buyer shall pay for and
take delivery of all validation batches. 

  

	 	9.6	 Upon qualification of the second Site and Facility, Site and Facility shall be considered in the same manner as
the Site defined in Section 3.3 hereof. Supplier shall be free, for the purpose of an establishing an efficient production planning, to produce any ordered API at either Site, provided, the selection of the Site is consistent with Buyer’s
Purchase Order(s) and delivery terms. 

  

	10.	 Price & Payment 

 

	 	10.1	 The API price is as defined in Exhibit 2 (the “Price”) annexed hereto and made a
part hereof. 

  

	 	10.2	 Unless otherwise mutually agreed to, the Parties will discuss and finalize any new Price increase prior to
November 30th of each year applicable to the following calendar year, and effective as of January 1st of each year during the term of this
Agreement. 

  

	 	10.3	 The Price shall be inclusive of the applicable INCOTERM and exclusive of any taxes and charges including
without limitation VAT. In the event that delivery is required to a place not specified in this Agreement or with a different INCOTERM, then Supplier reserves the right to adjust the Price accordingly. Currently the INCOTERM is an FCA
Supplier’s factory in Lahr. 

  
 5 

	 	10.4	 Supplier shall invoice Buyer upon delivery of the API. In the event that the Invoice is sent by email with
appropriate verification of receipt, then the date of delivery shall be considered the date of invoice for the purposes of this Agreement. 

  

	 	10.5	 In the event that Supplier fulfils a Purchase Order in several instalments then it shall invoice per instalment
or upon final instalment. 

  

	 	10.6	 Buyer shall pay each undisputed invoice within [***] net from the date of receipt of invoice. In the event of
any dispute, the Parties shall work together, in good faith, and use their best efforts to resolve any dispute. 

  

	 	10.7	 Payment shall be made In EUROS by wire transfer to Supplier’s bank account IBAN: 

 

	 	10.8	 Neither Party shall have any right of set-off against the other Party
for any undisputed invoice, 

  

	11.	 Delivery 

 

	 	11.1	 Supplier shall deliver the API in accordance with a FCA INCOTERM at Site (Lahr, Germany) (INCOTERMS 2010 as
published by the ICC). 

  

	 	11.2	 Delivery shall occur in accordance with the Purchase Order by the date specified therein 

 

	 	11.3	 Supplier shall ensure the API is properly labelled and packaged for transportation, in accordance with any
specifications agreed upon to prevent damage to the API through ordinary handling. The API shall be accompanied by all requisite documentation except where such documentation may be send separately or electronically. 

 

	 	11.4	 Supplier shall provide a certificate of conformity and a COA for each batch included in a delivery.

  

	 	11.5	 Delivery may occur in one or more instalments as agreed to by the Parties. 

 

	12.	 Passage of risk and title 

 

	 	12.1	 Risk in the API shall pass in accordance with the applicable INCOTERM. 

 

	 	12.2	 Title to the API shall pass upon payment in full of all undisputed monies owed by Buyer to Supplier; provided,
however, that the Buyer may use the API without limitation, prior to the date that title passes to the Buyer. In the event of a dispute, the matter shall be resolved in accordance with Section 10,6 hereof. Until such time, Buyer shall store the
API in a separated area at its warehouse and clearly identify the API as Supplier’s property. In the event of insolvency proceedings, of any event of termination of this Agreement, the Buyer shall provide access to its premises for recovery of
the API. 

  

	13.	 Reception and conformity 

 

	 	13.1	 Upon delivery of the API to the Buyer, the Buyer shall carry out visual inspection of the API to determine
whether they have been damaged during transportation, that the requisite quantities are included and that the API is accompanied by the appropriate documentation (the “Visual Inspection”). For the avoidance of doubt, this Visual
Inspection shall include in its scope any physical defect that is readily apparent without having to unpack the Product or open its containing vessel, Supplier’s failure to meet the requirements under the Visual Inspection shall be a
“Visual Defect”. In the event that a Visual Defect is observed, Buyer shall, within [***] of the Visual Inspection, provide Supplier with reasonable proof of the Visual Defect (i.e., photographs of such Visual
Defect or other such documentation). 

  
 6 

	 	13.2	 Buyer shall carry out batch testing prior to using the API and in any event within [***] of delivery Buyer
shall notify Supplier within [***] of receipt of written documentation of such testing of any batch testing failure and provide, upon request, all relevant documentation, testing information and samples (“Testing Failure”). For the
avoidance of doubt a Testing Failure occurs when the API fails to meet any of the specifications. 

  

	 	13.3	 In the event that Buyer notifies Seller of a Testing Failure then, upon Supplier’s written request, the
API shall be tested by an independent qualified party (chosen by Buyer from one of three (3) proposed by Supplier unless commonly agreed). If the Testing Failure is not confirmed, Buyer shall pay for costs related to such testing. If the
Testing Failure is confirmed, Supplier shall pay for costs related to such testing. In the event of such confirmation, or if Supplier accepts Buyer’s claim then Supplier shall at Buyer’s option: (i) replace the API free of charge in a
timely manner or (ii) reimburse Buyer in full for monies paid for the API. It is understood that in the event that a Testing Failure may be remedied in such a manner as to render the API fit for use in compliance with its Specifications then
Supplier shall carry out such remedy and shall not be required to complete any further reimbursement or replacement (e.g. if the COA was omitted and is then sent subsequently). 

 

	14.	 Quality Agreement and cGMP requirements 

 

	 	14.1	 “cGMP” means current Good Manufacturing Practices as established by ICH Q7 and applied by
various competent health and medical agencies around the world (such as the EMA, the FDA etc.). Supplier shall manufacture the API in accordance with cGMP regulations. Both Parties shall cooperate with each other to ensure that the other Party is
aware of the territory of use of the API (or distribution) and applicable jurisdictions / competent authorities with regards to the API. 

  

	 	14.2	 The Parties shall negotiate in good faith and execute a quality agreement (as required under cGMP) establishing
the roles and responsibilities of the Parties relating to the quality and regulatory aspects of the API (the “Quality Agreement”). The Parties may consider and execute intermediary quality agreements prior to the MA with a
definitive quality agreement being implemented subsequently. 

  

	 	14.3	 The Quality Agreement shall be attached hereto upon execution and thereafter such Quality Agreement shall
supercede any conflicting term in this Article 14 

  

	 	14.4	 Supplier will further cooperate with Buyer for the organization of quality audits required under cGMP rules
(“Quality Audits”). Such Quality Audits will take place on a yearly basis other than a ‘for cause’ Quality Audit which may occur at any time. Quality Audits may not exceed [***] past which Supplier shall recharge an
amount equal to [***] per additional day. 

  
 7 

	 	14.5	 Buyer shall provide Supplier with reasonably advanced notice of its proposed Quality Audit and shall discuss
appropriate dates with Supplier (it being understood that Supplier is running a multipurpose facility and may be already engaged for an audit for a different client). Buyer shall further execute, and have executed by its designated auditors, any
required confidentiality agreements, in the usual form and format, prior to access to the Site. 

  

	15.	 Subcontracting 

 

	 	15.1	 Supplier shall not subcontract the manufacture of the API to a third party and the API shall at all times be
manufactured at a Supplier Site. 

  

	 	15.2	 Notwithstanding the foregoing, it is understood and agreed that various secondary services may be contracted
out to specialized third parties at a Supplier Site (such as analytical services, maintenance, engineering etc.). Such services contracted out to third parties shall not be considered as ‘subcontracting’ and shall not require any consent
from Buyer provided the API continues to be manufactured in accordance with all of the Specifications at the Site which shall remain under Supplier’s control and ownership and for which the Supplier shall remain fully responsible for the
API’s compliance with all of the terms and conditions of this Agreement, all Specifications and any Exhibit. 

  

	16.	 Intellectual property 

 

	 	16.1	 All of the intellectual property on or related to the API and its chemical process shall be solely owned by
Supplier. All of the intellectual property on or related to the End Product or components thereof, except the API, shall belong to the Buyer. Supplier shall neither use nor transfer to a third party its knowledge of Buyer’s End Product;
including, but not related to its chemical make-up, its formulation or any other of its physical specifications all of which shall be considered as Buyer’s Confidential Information. 

 

	 	16.2	 The intellectual property rights and know-how related to the
manufacture of the API shall remain with Supplier. For the avoidance of doubt this refers to the equipment, methodology, engineering, research techniques etc. owned by Supplier as of the Effective Date, and that have been deployed and used by
Supplier during the research provided for the formulation of the End Product and its subsequent scale-up and industrialization and that can be deployed by Supplier for other Supplier clients for different
products 

  

	 	16.3	 Notwithstanding the foregoing, both Parties shall retain full right and title to any intellectual property they
may have developed prior to the Effective Date of this Agreement or without any reference to information received from the other Party under this Agreement. All intellectual property developed during the course of this Agreement or the manufacture
of the End Product, excluding the API, shall belong to the Buyer; and shall be promptly assigned and transferred to the Buyer, and the Supplier hereby agree to transfer and assign to the Buyer, without any additional consideration, fee or charge.

  

	 	16.4	 In the event that a third party claims ownership to the intellectual property of the API, Supplier shall notify
Buyer and Supplier shall comply with Buyer’s instructions to defend, settle or litigate such claim. Supplier shall indemnify, defend and hold Buyer harmless from and against any such third party API claim related to Supplier’s ownership
and use of the intellectual property rights in the API 

  
 8 

	17.	 Confidentiality 

 

	 	17.1	 Both Parties shall keep, now and at all times in the future, all information exchanged in relation to the API
and the End Product and this Agreement In strict confidence, specifically all technical information related to the API and the End Product’s physical specifications, manufacturing process, regulatory information as well as any
industrialization, engineering or technical information that either Party may make the other Party aware of. 

  

	 	17.2	 In the event of doubt, both Parties shall consider information received from the other Party as confidential
regardless whether such information was provided verbally, in written form, regardless of support or if obtained by accessory during a Site visit etc. 

  

	 	17.3	 Either Party shall notify the other Party of any suspected breach or any court order or competent authority
request to obtain such information. 

  

	 	17.4	 Either Party shall ensure that adequate safeguards are in place to restrict access to such confidential
information to the personnel required to have access in order to perform such Party’s obligations under this Agreement or any other specific arrangement (such as a research arrangement). 

 

	 	17.5	 Any information that is: (i) already in the public domain or (ii) lawfully obtained from a third
party shall not be considered as confidential. 

  

	 	17.6	 In the event of a court order, or request from a competent authority, for information received from the other
Party, then the Party receiving such order or request shall inform, to the extent possible the other Party and cooperate fully with such other Party, to the extent permitted under law, for the safeguard of such information’s confidentiality.

  

	18.	 Intentionally Deleted 

 

	19.	 Force Majeure 

 

	 	19.1	 Neither Party shall be in breach of this Agreement nor liable for delay or failure in performing any of its
obligations under this Agreement if such delay or failure result from any circumstances beyond the reasonable control of the party affected, including by way of example, acts of God, acts of terrorism, fires, floods, wars, sabotage, accidents,
labour disputes or shortages, plant shutdown, equipment failure, machine breakage, compliance with any law, order, rule or regulation of government agency or authority, or inability to obtain materials and utilities (including power and fuel),
equipment or transportation (“Force Majeure Event”). 

  

	 	19.2	 Upon occurrence of a Force Majeure Event, the affected Party shall immediately notify the non-affected Party and shall keep the non-affected Party appraised of the situation. 

 

	 	19.3	 This Agreement shall be suspended for the duration of the Force Majeure Event to the extent that a Party is
unable to carry out its obligations (e.g. if a Force Majeure Event creates unavoidable delays then Supplier will only be released from its obligation to meet the delivery date but not from its obligation to manufacture and supply the API under the
affected Purchase Order). Both Parties shall cooperate with each other to mitigate the effects of a Force Majeure Event on the other Party. 

  
 9 

	20.	 Representations and Warranty 

 

	 	20.1	 Supplier represents and warrants that the API will be manufactured and delivered in accordance with cGMP
regulations and shall conform to all USP Specifications, ICH guidelines, US FDA DMF requirements and this Agreement. 

  

	 	20.2	 Supplier further represents and warrants that the API will be labelled and packaged in accordance with Buyer
Specifications and cGMP rules. 

  

	 	20.3	 Supplier further represents and warrants that the API will be manufactured in accordance with the
Specifications and this Agreement. 

  

	 	20.4	 Supplier provides no further warranty or assurance than as expressly specified in this section and, except as
noted herein, provides no warranty as to the specific performance of the End Product except that it will perform in accordance with all Specifications. 

  

	 	20.5	 Supplier represents and warrants that it has all required permits and licenses to operate its Facilities at the
Site and to manufacture the API, and to enter into this Agreement. 

  

	 	20.6	 Each Party hereby represents and warrants to the other as of the Effective Date that: 

 

	 	(a)	 It is a duly organized and validly existing corporation, and is in good standing under the laws of the
jurisdiction of its organization, and has all requisite power and authority, corporate or otherwise, to execute, deliver, and perform this Agreement. 

  

	 	(b)	 This Agreement is a legal and valid obligation binding upon such Party and enforceable in accordance with its
terms, subject to the effects of bankruptcy, insolvency, or other laws of general application affecting the enforcement of creditor rights, judicial principles affecting the availability of specific performance, and general principles of equity
(whether enforceability is considered a proceeding at law or equity), 

  

	 	(c)	 The execution, delivery, and performance of this Agreement by such party does not conflict with any contract or
understanding to which such Party is a party or by which it is bound. 

  

	 	(d)	 The execution, delivery, and performance of this Agreement by such Party have been duly authorized by all
necessary action, corporate or otherwise, and do not violate any applicable law or any order, writ, judgment, injunction, decree, determination, or award of any court or governmental body, or administrative or other agency presently in effect
applicable to such Party. 

  

	 	(e)	 It is not aware of any government authorization, consent, approval, license, exemption of or filing or
registration with any court or governmental department, commission, board, bureau, agency or instrumentality, domestic or foreign, under any applicable law, currently in effect, necessary for, or in connection with, the transactions contemplated by
this Agreement or any other agreement or instrument executed in connection herewith, or for the performance by it of its obligations under this Agreement and such other agreements. 

  
 10 

	 	(f)	 No Party is under any obligation, contractual or otherwise, to any person that conflicts with or is
inconsistent in any material respect with the terms of this Agreement, or that would impede the diligent and complete fulfillment of its obligations hereunder. 

 

	21.	 Insurance and records 

 

	 	21.1	 Insurance: Both Parties represent and warrant that they will carry adequate Insurance for the purpose of
performing their obligations under this Agreement and shall provide, upon request, proof of such insurance. 

  

	 	21.2	 Records: Supplier shall keep full records of the API, including related raw materials, manufacture,
testing, storage etc. for a period of [***] following the production of each API Purchase Order. 

  

	22.	 Limitation of Liability 

 

	 	22.1	 Cap of Liability. Except in cases of [***], Supplier’s total liability in contract, tort (Including
negligence) or otherwise in relation to this Agreement will be limited to [***]. 

  

	 	22.2	 Exclusion of certain liabilities. In any event, even if Supplier is advised in advance of the
possibility of any loss or damage, Seller shall not be liable to the Purchaser for: 

 [***] 

 

	23.	 Notifications 

 

	 	23.1	 All notifications shall be in writing and shall be made by registered or certified letter to the address listed
in the above with a copy by email to the persons listed below for each respective Party. Delivery in person is also permitted and satisfies the conditions of this Agreement. 

 

	 	23.2	 For Supplier the notified persons are: (Sales) [***] and (Legal Director) [***] 

 

	 	23.3	 For Buyer the notified persons are: [***] and (Legal) [***]. 

 

	 	23.4	 In the event of a change in one of the person’s listed above, the Party affected by such change shall
inform the other Party. 

  

	 	23.5	 When a Party responds to a notification or otherwise acknowledges receipt, even if irregular under this
Agreement, then such notification shall be considered as valid. 

  

	24.	 Term and termination 

 

	 	24.1	 This Agreement shall be effective as of the Effective Date and shall remain in full force and effect for an
initial period ending five (5) years after the Effective Date. 

  

	 	24.2	 Upon expiry of such initial period, the Agreement shall be automatically renewed for subsequent renewal periods
of two (2) years each. 

  
 11 

	 	24.3	 Either Party may terminate this Agreement at the end of the initial period or a subsequent renewal period
without liability upon prior written notification sent at least [***] in advance. 

  

	 	24.4	 Either Party may further terminate this Agreement in the event that: 

 

	 	24.4.1	 The other Party has committed a material breach of any of its obligations under this Agreement and such breach
has not been remedied within [***] of written notification of such breach by the offended Party; 

  

	 	24.4.2	 The other Party enters into insolvency proceedings or any related restructuring or bankruptcy proceedings;

  

	 	24.5	 Effects of termination: In the event of termination by either Party, the following shall occur upon
termination: 

  

	 	24.5.1	 Supplier shall manufacture and Buyer shall take delivery of and pay for all Purchase Orders placed prior to
termination in accordance with this Agreement; and 

  

	 	24.5.2	 Supplier shall transfer to Buyer all Buyer intellectual property or to its designated contractor It being
understood that if this requires significant resources such time may be recharged to Buyer; 

  

	25.	 Jurisdiction and governing law 

 

	 	25.1	 This Agreement shall be governed exclusively by the laws of England and Wales. 

 

	 	25.2	 All disputes arising out of or in connection with the present contract shall be finally settled under the
Commercial Rules of Arbitration (the “Rules”) of the International Chamber of Commerce (“ICC”) in Geneva, Switzerland, by one (1) arbitrator appointed in accordance with the said Rules. 

 

	 	25.3	 This Agreement is made in English language and shall be interpreted in English language. 

 

	26.	 Miscellaneous 

 

	 	26.1	 Survival: all clauses related to intellectual property, confidential information, governing law and
jurisdiction shall survive termination or expiration of this Agreement and remain in force for [***] thereafter. 

  

	 	26.2	 Entire Agreement: This Agreement, together with its Exhibits and subsequent Purchase Orders or documents
issued in its performance, constitutes the entire understanding between the Parties in the subject matter thereof. In the event of a conflict between its terms, this Agreement shall supersede its Exhibits and together they shall supersede any
Purchase Orders. By exception the Quality Agreement shall take precedence for quality issues. Each Party agrees that it has not relied on any representation, warranty, collateral contract or other assurance (except those expressly set out in this
Agreement) made by or on behalf of the other party before the signature of this Agreement. Each party waives all rights and remedies which, but for this present clause, might otherwise be available to it in respect of any such representation,
warranty, collateral contract or other assurance 

  
 12 

	 	26.3	 Severability: If any provision of this Agreement is found by a court of competent jurisdiction to be
invalid or unenforceable, the invalid or unenforceable part or provision shall be replaced with a provision which accomplishes, to the extent possible, the original business purpose of such part or provision in a valid and enforceable manner, and
the remainder of this Agreement shall remain binding upon the Parties hereto. 

  

	 	26.4	 Change Control: neither Party may terminate this Agreement in the event of a change In control of the
other Party unless such change results in the other Party being controlled by, controlling, or being under common control with a direct competitor of the other Party. 

 

	 	26.5	 Assignment: Neither Party may assign its rights nor its obligations under this Agreement to a third
party without the other Party’s prior written consent; provided however, that in the event of the sale of all or substantially all of the securities, assets or business of Buyer to which this Agreement relates, or the merger business
acquisition or other combination of the Buyer with a third party, this Agreement shall be automatically assigned and transferred to the Buyer’s successor without the required consent or approval of Supplier so long as the assignee assumes in
writing all of the terms and conditions of this Agreement. 

  

	 	26.6	 Amendment: This Agreement may only be amended by written form executed by both Parties. It is
understood, that minor amendments, changes to the Exhibits or the notified persons’ details and changes to Purchase Orders may occur through exchange of email. Failure by a Party to exercise a right for a period of [***] following the event
giving rise to such right shall constitute a waiver of such right. 

  

	 	26.7	 Independent contractors: The Parties are acting as an independent contractor. This Agreement may not be
construed as creating or constituting a partnership, joint venture, or agency relationship between the Parties. Neither Party will have the power to bind the other or incur obligations on the other’s behalf without the other’s prior
written consent. 

  

	 	26.8	 Third Party rights: Any person not Party to this Agreement shall not have any right to enforce any term
of this Agreement. 

  

	 	26.9	 Counterparts: This Agreement may be executed in several counterparts in original copy or by electronic
copy. A scanned executed version sent by either Party shall be considered as executed by such Party as an original copy. 

SIGNATURE PAGE FOLLOWS 

  
 13 

 IN WITNESS WHEREOF, the Parties hereto have caused this Agreement to be executed by their duly authorized
representatives as of the Effective Date. 
  

			
	For Supplier	  	For Buyer Amylyx Pharmaceuticals, Inc.
	 Name: Frederic Desdouits
  

Title: CEO
	  	 Name: Justin Klee
  

Title: President

		
	Signature: /s/ Frederic Desdouits	  	Signature: /s/ Justin Klee

 List of Exhibits: 
  

	 	–	 Exhibit 1: Specifications 

	 	–	 Exhibit 2: Price 

	 	–	 Exhibit 3: Quality Agreement 

	 	–	 Exhibit 4: Form of Purchase Order 

 Exhibit 1: Specifications 

 
 

 
 PRODUCT SPECIFICATION 
  

 
  

					
	PRODUCT:	  	[***]	  	
	Trade Name:	  	[***]	  	
	CA-Registry-No.:	  	[***]	  	[***]
	Date of issue:	  	[***]	  	

  

			
	SPECIFICATION:	  	
	Appearance:	  	[***]
	Identify:	  	[***]
	Assay:	  	[***]
	Impurities:	  	[***]
	Water Content	  	[***]
	Heavy	  	[***]
	pH-Value (2%, aqueous solution)	  	[***]
	Residual Solvents:	  	[***]

 The information submitted in this publication is based on our current knowledge and experience. It does 

not relieve the purchaser from examining the product upon delivery and gives no assurance of suitability 

of the product for any particular purposes 
  

 
 CU Chemie Uetikon GmbH 

Raiffeisenstrasse 4 - D-77933 Lahr – Germany 

Tel.: (*+49)(7821)585 208 - Fax.: (++49)(7821)585 0 

E-Mail; info@uetikon.com - http://www.uetikon.com 

 Exhibit 2: Price 

The price of the Product, inclusive of packaging and to the agreed INCOTERM, will depend upon the quantity of Product ordered by the Buyer for delivery
during each calendar year, as shown in the table below: 
  

			
	 Quantity Range (1)
	  	 Price €/kg (2)

	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]

 Minimum order quantities are [***] 

Where the aggregate quantities of Product ordered by the Buyer for delivery in a calendar year are as specified in Column (1) above, and the price
applicable for all of such Product ordered for delivery in that calendar year will be as specified opposite that quantity in Column (2) above. 

Price Reconciliation 
 During each calendar
year, Supplier will invoice the Buyer at a price which assumes that during that calendar year, the aggregate quantity of Product which the Buyer will order will be as specified in the Forecast applicable to that calendar year. 

By the end of January in each calendar year, Supplier will calculate the aggregate quantity of Product actually ordered by the Buyer for delivery in the
previous calendar year, and will compare this to the quantities specified in the Forecast relevant to that calendar year. 
 Supplier will either
invoice the Buyer, or issue a credit note, (as applicable) for the sum necessary to result in a position where the price actually paid by Buyer for Product ordered for delivery during the previous calendar year is in accordance with the price
structure set out in above. 

 Exhibit 3: Quality Agreement 

[***] 

 Exhibit 4: Form of Purchase Order 

 
 

 
 43 Thorndike Street 

Cambridge, MA 02141 
 617-5 71 -88 72 
 [***] 

 
  

			
	Purchase Order	  	 Amylyx Pharmaceuticals Inc.

43 Thorndike Street

Cambridge, MA 02141

  
 P.O.
Number:
XXXXXX                                        
                                     

P.O. Date:
XXXXXX                                        
                                         
  
  

					
	Description	  	Quantity	  	Price
		  	X Kilos	  	
	Purchase Order Total:	  		  	

 Please Ship to: 
  

	
	Please Invoice Amylyx Pharmaceuticals, Inc.
	
	Amylyx Pharmaceuticals, Inc.
	43 Thorndike Street
	Cambridge MA 02141
	
	Amylyx EIN: 46-4600503
	Contact Phone
	[***]

  

	
	Authorized Signature:
	
	Amylyx Pharmaceuticals, Inc.
	
	  
 Joshua Cohen, CEO

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00337-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00337-of-00352.parquet"}]]